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Tbx3 has been identified as a regulator of fate decisions during liver development in the 
mouse, but whether it function similarly in humans remains unclear. We generated TBX3 
knockout human pluripotent stem cell (PSCs) lines using CRISPR/Cas9 genome editing 
technology. We differentiated TBX3 knockout lines to hepatocytes and found a decrease 
in hepatic markers and in hepatocyte function, demonstrating that TBX3 is also 
important for liver differentiation in humans. Surprisingly, we detected expression of 
pancreatic markers, including PDX1 in our TBX3 knockout hepatocytes, suggesting the 
possibility that TBX3 may regulate liver development by suppressing a pancreatic fate. 
We next differentiated the TBX3 knockout lines to pancreatic progenitors to determine 
whether the loss of TBX3 impacts pancreatic differentiation. We found that TBX3 
knockout PSCs generated more pancreatic progenitors, and that these progenitors had 
an enhanced pancreatic gene expression signature at the expense of hepatic gene 
expression. We also found that epithelial-to-mesenchymal transition was commonly 
dysregulated in TBX3 mutant pancreas and hepatocyte cells. This suggests that TBX3 
may function during EMT in both liver and pancreas development. These data highlight a 
potential role of TBX3 in distinguishing between hepatic and pancreatic domains during 
foregut patterning, with implications for enhancing the generation of pancreatic 
progenitors from PSCs. 
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CHAPTER 1: INTRODUCTION AND OVERVIEW  
 
1.1 Characteristics of the liver  
The liver is the largest internal organ in the body, and is a major center for metabolism, 
digestion, and detoxification. As part of this thesis focuses on the transcription factor 
TBX3 and its role in endoderm patterning and liver development, we will first review the 
basic structure and function of the liver.  
1.1.1 Liver structure 
The liver has four lobes that are made up of hepatic lobules, hexagonal structures that 
are constituted of several different types of cells arranged around a central vein (Figure 
1.1). The portal triad, which is comprised of a hepatic artery, hepatic portal vein, and 
intrahepatic bile duct (IHBD), are located at each corner of the hepatic lobule. 
Hepatocytes are arranged in cords-like structures between the central vein and the 
portal triad, and are separated by sinusoidal vessels that carry blood through the lobule. 
Hepatocytes comprise about 80% of the liver, and carry out the majority of liver 
functions. The sinusoids are made up of specialized liver endothelial cells, and Kupffer 
cells and Stellate cells are located within the sinusoidal space. A small subset of cells 
adjacent to the portal vein differentiate into cholangiocytes, epithelial cells that line the 
bile ducts (Gordillo et al., 2015).  
Hepatocytes are the main functional cell type in the liver. Although they all have the 
same structure, the specific function of a hepatocyte is determined by its location within 
the hepatic acinus, the functional unit of the liver. The different zones are determine by 
signaling gradients, and can change in response to environmental factors, 
demonstrating that zonation is a dynamic phenomenon (Kietzmann, 2017). Blood flow 
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Figure 1.1 Structure of hepatic sinusoid 
Functionally mature hepatocytes (red) exist in cords between the central vein and the 
portal triad, made up of the hepatic artery, portal vein, and intrahepatic bile duct (dashed 
circle). The central vein and portal triad are connected by sinusoidal spaces which 
contain specialized endothelial cells (brown), Kupffer cells (blue), and stellate cells 




creates an oxygen and nutrients gradients which contribute to the zonation process 
within the hepatic acinus, to  determine the specific function of the hepatocytes (Trefts et 
al., 2017). 
1.1.2 Liver function 
The liver carries out several metabolic functions. It regulates glucose metabolism by 
taking up blood glucose and synthesizing glycogen in response to increased levels of 
insulin. Conversely, glycogen, which is stored in the liver, is broken down into glucose in 
response to increased levels of glucagon (Bechmann et al., 2012; Trefts et al., 2017). 
The liver also synthesizes lipids de novo and from fatty acids taken up from the blood, 
and also breaks them down. The liver synthesizes alternative sources of energy such as 
ketones and triglycerides from fat, and is a prominent site of cholesterol synthesis in the 
body (Nguyen et al., 2008; Trefts et al., 2017). Bile, which emulsifies and digests lipids, 
is also produced by hepatocytes and secreted into spaces called the canaliculi. As it 
travels through the canaliculi, cholangiocytes modify bile by secreting and absorbing 
solutes and water via transmembrane channels. These processes are regulated by 
hormones and signaling pathways including Ca2+ and cAMP (Banales et al., 2019). The 
modified bile then drains into the IHBDs, which connect to the gallbladder where bile is 
stored (de Buy Wenniger and Beuers, 2010; Pitt and Nakeeb, 2017). Finally, the liver 
makes and secretes many proteins into the bloodstream, including albumin, growth 
factors, clotting factors and other regulatory proteins. Amino acids metabolism also takes 
place in the liver (Trefts et al., 2017).  
Another major function of the liver is detoxification. Drugs and toxins are metabolized in 
the liver through a three-step process. In phase I metabolism, compounds undergo 
oxidation/reduction or hydrolysis reactions by enzymes, such as cytochrome P450 
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enzymes, to convert them to a safer or more active form. In phase II metabolism, 
compounds from phase I undergo various modifications so that they are more stable 
easier to export into the bile. During phase III metabolism, toxins and other compounds 
generated in phase II are excreted into the bile or transported to the kidneys where they 
are then removed from the body. Additionally, the liver is responsible for sequestering 
and excreting metals, such as iron or copper, which are essential to the body, but can be 
toxic at high levels (Blondet et al., 2018).  
1.2 Characteristics of the Pancreas 
The pancreas is an organ that functions in both metabolism and digestion. As part of this 
thesis focuses on the transcription factor TBX3 and its role in endoderm patterning and 
pancreatic progenitor generation from pluripotent stem cells, we will next review the 
basic structure and function, of the pancreas.  
The pancreas is an endodermal organ that originates from two sections of the posterior 
foregut endoderm that bud off and come together. The pancreas has exocrine function 
to aid in digestion, and endocrine function to regulate glucose homeostasis. The 
endocrine component of the pancreas is comprised of acinar cells, which secrete 
digestive enzymes and fluids, and ductal cells which form the pancreatic ducts though 
which the “pancreatic juices” drain into the duodenum to during digestion (Bastidas-
Ponce et al., 2017). The endocrine function of the pancreas is carried out by structures 
called the Islets of Langerhans. These islets are made up of five types of cells: a-cells 
which secrete glucagon, b-cells which secrete insulin, d-cells which secrete 
somatostatin, PP-cells which secrete pancreatic polypeptide, and e-cells which secrete 
ghrelin (Figure 1.2). The Islets of Langerhans form tight clusters and are found 




Figure 1.2: Pancreas structure 
 
Figure 1.2: Pancreas structure  
The mature pancreas has both exocrine and endocrine function. Acinar cells (blue) 
secrete digestive enzymes into the pancreatic ducts. The pancreatic ducts are branched 
tubes lined with epithelial ductal cells (purple) that connect to the common bile duct and 
drain into the duodenum. Structures called the Islets of Langerhans make up the 
endocrine component of the pancreas. Islets are made up of five cell types which each 
secrete a different hormone: a-cells (glucagon), b-cells (insulin), d-cells (somatostatin), 
PP-cells (pancreatic polypeptide), and e-cells (ghrelin). The cells of the islet function in 
regulating blood glucose levels. Created with BioRender.com. 
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 pancreas, which helps control the release of hormones that regulate blood glucose 
levels (Pan and Wright, 2011). The two main hormones involved in glucose homeostasis 
are insulin and glucagon. When blood glucose levels are high, b-cells release insulin to 
stimulate glucose uptake by skeletal muscles and trigger glycogen synthesis in the liver. 
When blood glucose levels are low, a-cells release glucagon to stimulate glucose 
production and release in the liver (Aronoff et al., 2004). Impaired glucose regulation 
leads to diabetes mellitus, a disease that impacts millions of people world-wide.  
1.3 Endoderm, liver, and pancreas development 
The main focus of this thesis is studying the role of TBX3 in endoderm, liver, and 
pancreas development. The development of all three tissues has been extensively 
studied in several model organisms. To better understand how the work presented in 
this thesis fits into these areas, we will review what is known about endoderm, liver, and 
pancreas development. 
1.3.1 Endoderm development 
Gastrulation is a process that establishes the three germ layers: the ectoderm, 
mesoderm, and endoderm. This thesis focuses on both liver and pancreas development, 
organs which are derived from the inner most germ layer called the endoderm. 
Additionally, this thesis examines the possible role of the transcription factor TBX3 in 
establishing the hepatic and pancreatic domains of the foregut endoderm. As such, we 




1.3.1.1 Endoderm formation 
During gastrulation, epiblast cells migrate to the interior of the embryo through a 
structure at the posterior end called the primitive streak (Lawson et al., 1986). These 
cells go through a transient bipotent intermediate stage called the mesendoderm (Lickert 
et al., 2002), before settling in the middle layer to become the mesoderm or the inner-
most layer to become the definitive endoderm (DE). As the DE develops, it is divided 
into three regions: the foregut, midgut, and hindgut. The foregut gives rise to the 
esophagus, trachea, lungs, thyroid, stomach, liver, pancreas, and gallbladder, while the 
midgut gives rise to the small intestine, and the hindgut gives rise to the colon (Zorn and 
Wells, 2009). Cells that migrate through the primitive streak first become anterior 
endoderm (foregut), while cells migrating in later are part of the posterior endoderm 
(hindgut) (Lawson et al., 1987). The DE cells undergo a series of migration and 
extension movements to form an anterior-posterior axis. The anterior and posterior ends 
then fold and move towards each other to form the primitive gut tube (Zorn and Wells, 
2009).  
1.3.1.2 Nodal signaling in endoderm development  
Nodal, a member of the transforming growth factor-β family, is crucial for many events in 
endoderm development. Nodal signaling is responsible for primitive streak formation and 
maintenance (Conlon et al., 1994). Evidence shows that the Wnt pathway maintains 
Nodal signaling. In the mouse, Wnt3a stimulates Nodal expression during primitive 
streak formation (Ben-Haim et al., 2006). Once the cells migrate through the primitive 
streak, Nodal, regulates mesendoderm differentiation. Studies across many species 
show that low levels of Nodal induce mesoderm, while high Nodal is required for DE 
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specification (Green and Smith, 1990; Shen, 2007). The anterior region of the primitive 
streak produces high levels of Nodal to drive DE development. 
Nodal signaling mediates DE differentiation by regulating expression of various 
transcription factors. Nodal induces expression of Mixer family transcription factors 
which are important for DE development by suppressing a mesoderm fate (Shen, 2007; 
Zorn and Wells, 2009). In both Xenopus and mouse, loss of Mixer genes results in 
impaired DE formation and expanded mesoderm formation (Hart et al., 2002; Kofron et 
al., 2004). Nodal signaling also induces expression of Foxa2, Sox17, and 
Eomesodermin, which are important for DE development, as mutations in all three genes 
result in impaired endoderm development. Not only do these transcription factors control 
endodermal gene expression, they also influence cellular movements of during anterior-
posterior axis formation (Arnold et al., 2008; Dufort et al., 1998; Kanai-Azuma et al., 
2002), tying Nodal signaling to DE morphogenesis as well. 
Nodal signaling distinguishes between a mesoderm and endoderm fate through close 
interactions with other signaling pathways, including fibroblast growth factor (FGF) and 
bone morphogenetic protein (BMP). As mentioned previously, high levels of Nodal 
signaling induce DE, while lower levels induce mesoderm. Nodal acts in a dose-
dependent manner in conjunction with FGF signaling to distinguish these fates. In the 
presence of FGF and low nodal signaling, the mesodermal gene Xenopus Brachyury 
(Xbra), homologous to Brachyury in mice, is expressed. However, high levels of nodal 
signaling repress Xbra expression (Latinkic et al., 1997). Additionally, in zebrafish, BMP 
and FGF signaling inhibit endoderm differentiation by reducing the number of 
endodermal precursors. FGF inhibits downstream effectors of Nodal that are required for 
endoderm differentiation, (Poulain et al., 2006), highlighting the interplay between 
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multiple signaling pathways during endoderm development. Nodal signaling plays many 
crucial roles during endoderm development; it is involved in primitive streak formation, 
morphogenetic movements in body axis formation, and distinguishing between 
endoderm and mesoderm fates.   
1.3.1.3 Endoderm patterning  
Once the endoderm is specified and the primitive gut tube forms, gradients of the 
signaling pathways Wnt, FGF, BMP, and retinoic acid pattern the gut tube into the 
foregut, midgut, and hindgut (Figure 1.3). The three domains are distinguished by broad 
expression pattern of transcription factors. The foregut at the anterior end gut tube is 
defined by Sox2 expression, Pdx1 is expressed in the midgut, and Caudal homeobox 
(Cdx) genes are expressed in the hindgut at the posterior end of the gut tube (Figure 
1.3). The signals that pattern the endoderm come from adjacent mesodermal tissues 
(Kumar et al., 2003; Wells and Melton, 2000), demonstrating the close relationship 
between the two germ layers. As development continues, each region receives different 
levels of the signals. This results in expression of lineage-specific transcription factors in 
distinct domains, permitting each section of the gut tube to develop into different organs. 
Wnt signaling is high in the posterior gut tube and promotes an intestinal fate while 
repressing a foregut fate (Cervantes et al., 2009; Gregorieff et al., 2004). Repressing b-
catenin, a downstream effector of canonical Wnt signaling, results in ectopic liver and 
pancreas (foregut-derived organs) development in the posterior gut tube. Additionally, b-
catenin directly represses Hhex, a foregut specific gene, to posteriorize the gut tube 
(McLin et al., 2007). Similarly, FGF signaling suppresses a foregut fate while promoting 
a posterior fate. Mesoderm-derived FGF4 signals act on neighboring endoderm cells to 
induce expression of posterior gut tube markers Pdx1 and CdxB, and suppresses  
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Figure 1.3: Anterior-posterior axis patterning in the endoderm during gut tube 
formation 
Signals from surrounding mesodermal tissues pattern the gut tube in an anterior-
posterior fashion. WNT, FGF, and BMP signals promote an intestinal fate in the mid- and 
hindgut at the posterior end of the gut tube while inhibiting an anterior fate. Conversely 
retinoic acid signaling establishes the foregut domain in the anterior gut tube and 
suppresses a posterior fate. These signals induce transcription factors which broadly 
pattern the gut tube. The foregut is characterized by SOX2 expression, while the midgut 
and hind gut express PDX1 and Caudal homeobox (CDX) genes, respectively. Different 
levels of signaling activity induce lineage-specific transcription factors in distinct domains 
in the gut tube, specifying these regions to develop to different endodermal organs. 
Adapted from Zorn and Wells, 2009. Created with Biorender.com. 









foregut markers Hex and Nkx2.1. FGF4 is also important for establishing the midgut-
hindgut boundary, illustrating its pivotal role in gut tube patterning (Dessimoz et al., 
2006). BMP signaling also inhibits anterior gut tube development while promoting a more 
posterior fate. Enhanced BMP signaling diminishes the anterior domain and expands the 
posterior gut domain. Conversely, low BMP signaling expands the anterior domain into 
the posterior regions of the gut tube (Tiso et al., 2002). On the other hand, retinoic acid 
(RA) signaling promotes an anterior fate. Inhibiting RA signaling results in a loss of 
pancreatic and liver domains, and ectopic expression of posterior endoderm markers. 
Overexpression of RA has the opposite effect, with anterior markers expanding to 
posterior regions (Stafford and Prince, 2002).  Taken together, the Wnt, FGF, and BMP 
signaling pathways pattern the gut tube in an anterior-posterior fashion by promoting 
mid- and hindgut fates. The anterior gut tube receives RA signals instead and patterns 
anterior endoderm into the foregut.  
Understanding gut tube patterning has been instrumental in developing protocols to 
differentiate pluripotent stem cells (PSCs) to DE and other endoderm-derived cell types. 
Studies from model organisms have allowed us to mimic the appropriate levels and 
timing of signals to efficiently direct PSCs to primitive streak (Gadue et al., 2006), 
mesendoderm (Tada et al., 2005), and DE (D’Amour et al., 2005). PSC-derived DE can 
be further differentiated to endodermal lineages, including hepatocytes and pancreatic b-
cells, which is discussed in Section 1.6.4 of this thesis.  
1.3.2 Liver development 
The liver arises from the foregut domain of the endoderm. Prior to hepatic specification, 
there are two populations of progenitors that give rise to the liver bud: two lateral liver 
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progenitor domains and a ventral midline liver domain. Fate-mapping studies show that 
these populations exist in spatially distinct locations in the embryo, which come together 
to form the region of foregut that becomes the liver. Interestingly, the lateral domains can 
only give rise to cells of the liver and the pancreas, while the ventral midline domain can 
give rise to the liver bud as well as other endodermal midline tissues (Tremblay and 
Zaret, 2005). Once these domains come together, transcription factors that act as 
pioneer factors prepare this region for hepatic specification.  
Pioneer transcription factors bind to regions of the chromatin to facilitate gene 
transcription. One way they do this is by binding target sites, even in tightly packed 
heterochromatin, and facilitate opening them up to allow other factors to bind and 
activate transcription (Zaret and Carroll, 2011). FoxA and Gata4 transcription factors are 
bound to the liver-specific Albumin enhancer prior to hepatic specification (Bossard and 
Zaret, 1998; Cirillo et al., 2002; Gualdi et al., 1996), making this region open for 
transcription after the endoderm receives hepatic specification signals (Figure1.4A). 
Mice lacking FoxA family members Foxa1 and Foxa2 fail to undergo hepatic 
specification, as there is no detectable liver bud or expression the hepatic marker Afp. 
These phenotypes are not seen in Foxa1 and Foxa2 single mutants (Lee et al., 2005), 
showing that both transcription factors are required to establish hepatic competence 
prior to specification. 
1.3.2.1 Hepatic specification 
Hepatic specification begins around E8.5 in the mouse, or 23 days of gestation in 
humans (Gordillo et al., 2015). The ventral foregut lies next to the cardiac mesoderm 
and the septum transversum mesenchyme, which secrete fibroblast growth factor (FGF) 
and bone morphogenetic protein (BMP) signals, respectively, to induce hepatic 
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specification (Figure1.4B). Ventral foregut cells from mouse embryos cultured with 
cardiac mesoderm express hepatic genes Albumin and Afp, while cells cultured without 
cardiac mesoderm do not, suggesting the cardiac mesoderm secretes signals necessary 
for hepatic specification. (Gualdi et al., 1996). Specifically, Fgf1 and Fgf2 are expressed 
by the cardiac mesoderm and can induce expression of Albumin, Afp, and Ttr in the 
adjacent ventral foregut endoderm (Jung et al., 1999). Furthermore, Fgf8 promotes 
cellular outgrowth of the liver bud (Jung et al., 1999). These findings suggest that FGF 
signals from the cardiac mesoderm are needed for proper hepatic specification and 
morphogenetic movements during liver development. Additionally, FGF signaling acts 
via the mitogen activated protein kinase (MAPK) pathway to influence liver development. 
Phosphorylated-ERK, the active form, is expressed in lateral hepatic progenitors and in 
the ventral foregut endoderm, correlating with Fgf expression in the adjacent tissues. 
The FGF/MAPK pathway induces Afp and Albumin expression, and is needed for 
hepatic differentiation and outgrowth during liver bud formation (Calmont et al., 2006).  
These studies establish the important role of the FGF pathway in hepatic specification. 
BMP signaling is also critical to for hepatic induction. The septum transversum 
mesenchyme (STM) secretes Bmp4 to the adjacent ventral foregut endoderm to specify 
the hepatic endoderm. Bmp4 null embryos exhibit delayed formation of the liver bud, and 
BMP inhibition prevents Albumin expression in the ventral foregut endoderm (Rossi et 
al., 2001). Additionally, Bmp4 maintains expression of Gata4 in the ventral foregut 
endoderm, allowing for hepatic gene expression upon receiving inductive FGF signals 
(Rossi et al., 2001). Though Bmp4 is primarily responsible for hepatic induction, Bmp2 
can act redundantly (Chung et al., 2008; Rossi et al., 2001). BMP signaling works in 
conjunction with the FGF pathway to induce liver gene expression in the hepatic 
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endoderm, and is required for proper cell movement and morphogenesis during liver bud 
formation. In zebrafish embryos, Bmp and Fgf signaling were blocked in the region that 
gives rise to the liver prior to hepatic specification, resulting in a depleted expression of 
the hepatic specification markers hhex and prox1 (Shin et al., 2007). Both Fgf and Bmp 
signaling are required for expression of Hex and Albumin in the hepatic endoderm in 
chick embryos (Zhang et al., 2004), demonstrating that the role of these pathways in 
hepatic specification and development is conserved across multiple species. 
Interestingly, Wnt signaling has been implicated in hepatic specification in zebrafish. 
Wnt2bb mutant embryos do not have any detectable hepatic tissue, and have little to no 
expression of hex or prox1. Wnt2bb is expressed from the lateral plate mesoderm, which 
is adjacent to the hepatic endoderm (Ober et al., 2006). Although there is little evidence 
for Wnt signaling in hepatic specification in other species, the study highlights the 
importance of mesoderm-derived signals during hepatic induction and specification.  
Additionally, the transcription factor Hnf1b is required for hepatic specification. Hnf1b-/- 
embryos do not form a liver bud or express early hepatic markers including Afp, 
Albumin, Prox1, and Hex. Both Foxa1 and Foxa2 are expressed in the ventral foregut of 
Hnf1b-/- embryos, albeit at reduced levels, suggesting that Hnf1b may be required to 
sustain their expression. Finally, FGF signals do not induce Albumin or Ttr expression in 
ventral foregut endoderm explants from Hnf1b-/- embryos (Lokmane et al., 2008), 
suggesting that Hnf1b  plays a key role in both establishing competence and hepatic 
specification. Once the hepatic endoderm receives inductive signals and is specified, a 
set of transcription factors facilitates a series of morphogenetic movements to form the 
liver bud.  
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Figure 1.4: Overview of liver development  
 
Figure 1.4: Overview of liver development 
Schematic summary of different stages of liver development.  
(A) Prior to specification, pioneer factors Foxa1 and Fox2 bind to the enhancer of the 
liver-specific gene Albumin, opening it up for transcription.  
(B) The cardiac mesoderm and septum transversum mesenchyme (STM) secrete 
fibroblast growth factor (FGF) and bone morphogenetic protein (BMP) signals, 
respectively, to the neighboring ventral foregut endoderm to specify the hepatic 
endoderm (red).  
(C) The liver bud forms when the specified hepatic endoderm thickens and elongates 
away from the gut lumen. The cells, called hepatoblasts, become columnar in shape, 
then delaminate and migrate into the STM as the basal lamina breaks down.  
(D) The liver bud undergoes rapid proliferation and expansion when the hepatoblasts 
receive Wnt, hepatocyte growth factor (HGF), and FGF signals.  
(E) Hepatoblasts receive different signals and differentiate to either hepatocytes or 
cholangiocytes, the epithelial lining of the bile duct. Most hepatoblasts receive 
Oncostatin M (OSM), HGF, and Dexamethasone (Dex) signals to differentiate and 
mature into functional hepatocytes. A small subset of hepatoblasts receive Notch and 
Wnt signals to differentiate to cholangiocytes. Adapted from Gordillo et al., 2015. 




1.3.2.2 Liver bud formation  
At E9.5 in the mouse, or 26 days of gestation in humans, the specified hepatic 
endoderm begins to thicken and change shape, becoming a pseudostratified layer of 
cells called hepatoblasts. Hepatoblasts are bipotential progenitors that differentiate into 
either hepatocytes or cholangiocytes, epithelial cells that line intrahepatic bile ducts. 
Hepatoblasts express fetal markers (Afp), as well as both hepatocyte (Hnf4a, Albumin, 
Ck18) and cholangiocyte markers (Ck19) (Gordillo et al., 2015). Liver bud formation can 
be separated into three stages. First, the hepatic endoderm thickens as it elongates 
away from the gut lumen and the cells take on a columnar shape. This occurs at the 
same time when hepatic gene expression is induced, and the ventral foregut closes. 
Next, the hepatoblasts form a pseudostratified layer, with nuclei being in different apical 
and basal positions within the cell. As these hepatoblasts divide, they undergo 
“interkinetic nuclear migration” (INM), with the nuclei moving to the apical side of the cell. 
Finally, the basement membrane degrades and the hepatoblasts delaminate and 
migrate into the STM to form the liver bud (Bort et al., 2006). The cellular changes that 
occur during liver bud formation are carefully controlled by several transcription factors 
(Figure 1.4C). 
The transcription factor Hex is responsible for proper patterning of the ventral endoderm 
and growth of the liver bud (Bort et al., 2004; Martinez Barbera et al., 2000). Hepatic 
genes are expressed in Hex-/- embryos but the liver bud fails to grow due to a reduction 
in proliferating cells (Bort et al., 2004). Additionally, hepatoblasts in Hex-/- embryos fail to 
undergo INM to form a pseudostratified layer, do not form a diverticulum, and do not 
delaminate into the STM (Bort et al., 2006). These findings suggest that Hex is not 
required for hepatic specification, but rather for liver bud formation and growth.  
17 
 
Members of the GATA transcription factor family have also been implicated in liver bud 
formation and growth. Gata4/5/6 are involved in liver bud formation in zebrafish 
(Holtzinger and Evans, 2005), and Gata4/6 plays a similar role in the mouse (Zhao et al., 
2005), demonstrating a conserved function across species. Gata6-/- embryos have a 
small liver outgrowth, but the hepatoblasts fail to delaminate. Hepatic gene expression 
appears normal in Gata6-/- embryos, likely due to Gata4 compensating for the lack of 
Gata6. Gata6, but not Gata4, is expressed in delaminating hepatoblasts, explaining why 
there is a defect in liver bud migration, but not specification in Gata6-/- embryos (Zhao et 
al., 2005). Although Gata4 and Gata6 act redundantly in hepatic specification, they have 
distinct roles in hepatoblast migration. 
The transcription factor Prox1 is also required for hepatoblasts to delaminate and 
migrate into the STM as the liver bud grows. Prox1-/- embryos have small liver buds with 
fewer proliferating hepatoblasts compared to wildtype embryos (Sosa-Pineda et al., 
2000). Instead of migrating into the surrounding mesenchyme, hepatoblasts remain 
clustered around the hepatic diverticulum because the basal lamina surrounding the liver 
bud is not degraded. Alternatively, the migration defect may be explained by elevated 
levels of E-cadherin, which is normally downregulated in migrating hepatoblasts. 
Interestingly, hepatic gene expression is not perturbed in Prox1-/- embryos (Sosa-Pineda 
et al., 2000). Taken together these findings suggest that Prox1 mediates hepatoblast 
delamination and migration, not hepatic specification. The transcription factor Tbx3 also 
plays a role in hepatoblast migration as Tbx3-/- embryos have a similar phenotype as the 
Prox1-/- embryos. The role of Tbx3 in liver development is discussed in further detail in 
Section 1.5.3 of this thesis. 
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Similarly, the transcription factors Onecut1 (also known as Hnf6) and its close homolog 
Onecut2 (Oc2), play a role in hepatoblast migration. Hnf6 and Oc2 are expressed in 
early liver development and act redundantly. Mice deficient for both genes have a similar 
phenotype to Prox1-/- embryos in that they had small liver buds, a delay in basement 
membrane degradation, and the hepatoblasts fail to migrate into the STM. Additionally, 
Hnf6 and Oc2 regulate genes involved in cell migration and adhesion, including E-
cadherin. (Margagliotti et al., 2007). After the hepatoblasts delaminate into the 
surrounding mesenchyme, they undergo rapid proliferation to form the liver.   
1.3.2.3 Liver bud expansion  
Around E10.0 in the mouse (31 days of gestation in humans), hepatoblasts migrate into 
the STM and the undergo rapid proliferation. (Gordillo et al., 2015). This process is 
controlled by several signaling pathways (Figure 1.4D). Although Wnt signaling initially 
plays an antagonistic role to liver development (see Section 1.3.1.3), it is crucial for 
hepatoblast proliferation during liver bud expansion (Tan et al., 2006). Inhibiting b-
catenin in chick embryos leads to small livers (Suksaweang et al., 2004). Similarly, in 
zebrafish, b-catenin drives proliferation and growth in the developing liver (Goessling et 
al., 2008; McLin et al., 2007). Nuclear b-catenin levels are highest between E10.0 - 
E12.0 in the mouse, the same time as peak liver bud expansion (Micsenyi et al., 2004). 
Mice with a liver-specific deletion of b-catenin have reduced liver size due to fewer 
proliferating hepatoblasts (Tan et al., 2008). Additionally, Wnt signaling is activated 
during liver regeneration in the mouse and promotes hepatocyte proliferation (Goessling 
et al., 2008). These studies demonstrate the role conserved role of Wnt signaling in 
regulating proliferation and growth during liver development. 
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The hepatocyte growth factor (HGF) and FGF pathways also control hepatoblast 
proliferation by regulating b-catenin activity. Nuclear b-catenin promotes proliferation 
during liver regeneration (Monga et al., 2001) and in hepatocellular carcinoma (Nhieu et 
al., 1999). In rat hepatocytes, the HGF receptor Met physically interacts with b-catenin. 
When HGF binds Met, both Met and b-catenin become phosphorylated, and the Met-b-
catenin complex dissociated, allowing for b-catenin translocation into the nucleus 
(Monga et al., 2002). Similarly, FGF signaling mediates b-catenin activation in 
hepatoblasts to regulate proliferation. Fgf10 is produced by hepatic stellate cells and 
binds to the Fgf2rb receptor, which is expressed on the surface of hepatoblasts, inducing 
a signaling cascade that activates b-catenin. Fgf10-/- and Fgfr2b-/- mouse embryos have 
small livers, and hepatoblast proliferation in Fgf10-/- embryos is impaired (Berg et al., 
2007). Taken together, these studies demonstrate that the Wnt, HGF, and FGF 
pathways regulate hepatoblast proliferation via b-catenin during liver bud expansion.  
1.3.2.4 Hepatocyte differentiation and maturation  
Once liver bud expansion occurs, hepatoblasts begin to differentiate to either 
hepatocytes or cholangiocytes at E13.5 (around 56 days of gestation in humans) 
(Gordillo et al., 2015). Signaling via HGF, Oncostatin M (OSM), and glucocorticoids drive 
the majority of hepatoblasts towards a hepatocyte fate (Figure 1.4E). HGF is produced 
by sinusoidal mesenchymal cells of the developing liver, and is crucial for regulating 
proper morphology and size during liver development via the c-Met receptor, which is 
expressed on hepatocytes (Schmidt et al., 1995). HGF is also critical for maintaining 
signaling pathways and expression of genes involved in hepatocyte differentiation 
(Michalopoulos et al., 2003). During liver regeneration, HGF is upregulated upon injury 
and acts as a potent mitogen to induce hepatocyte proliferation (Michalopoulos and 
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DeFrances, 1997). Additionally, OSM produced by fetal hematopoietic cells in the liver, 
binds to its receptor gp130, which is expressed on the hepatocyte surface, to facilitate 
maturation. Hepatocytes from gp130-/- embryos are less functional compared to 
hepatocytes from wildtype embryos (Kamiya et al., 1999). OSM signaling regulates liver 
gene expression and maturation via the STAT3 pathway. Blocking this pathway using a 
dominant negative form of STAT3 attenuates hepatic gene expression and differentiation 
(Ito et al., 2000). Additionally, OSM signaling mediates the Ras signaling pathway in 
maturing hepatocytes. Specifically, OSM regulates K-Ras to  ensure proper localization 
of the adherens junctions proteins E-cadherin and ZO-1. (Matsui et al., 2002). The 
glucocorticoid Dexamethasone also regulates E-cadherin and ZO-1 expression in fetal 
hepatocytes, demonstrating that this pathway works in conjunction with OSM to facilitate 
hepatocyte maturation (Matsui et al., 2002). Dexamethasone also works in combination 
with the HGF pathway to stimulate hepatocyte maturation (Kamiya et al., 2001). Both 
OSM and HGF signaling are required for hepatocyte maturation, but they act through 
distinct pathways and at different stages of development. OSM signaling is active in the 
developing mouse embryo at E14.0 and E18.0, but is not active postnatally, while HGF 
signaling continues after birth. (Kamiya et al., 2001). In addition to mediating hepatocyte 
function and cellular structure, these pathways induce expression of transcription factors 
necessary for hepatocyte maturation. 
Two important transcription factors required for hepatocyte maturation are C/ebpa and 
Hnf4a.  C/ebpa expression is first detected when hepatoblasts begin differentiating, 
suggesting it is important for hepatocyte development (Nagy et al., 1994; Shiojiri et al., 
2004). C/ebpa-/- mice are born, but die shortly after birth, and have significantly smaller 
livers that do not function properly (Flodby et al., 1996). Interestingly, hepatocytes from 
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C/ebpa-/- mice have increased expression of biliary markers (Tomizawa et al., 1998). 
C/ebpa binds to the promoter of Hnf6, which promotes a cholangiocyte fate, and 
negatively regulates its expression, providing evidence that C/ebpa promotes a 
hepatocyte fate by suppressing cholangioycyte differentiation (Rastegar et al., 2000). 
The STAT3 pathway is inactive in livers of C/ebpa-/- embryos (Burgess-Beusse and 
Darlington, 1998). However, this phenotype is rescued upon addition of OSM (Mackey 
and Darlington, 2004), suggesting the possibility that OSM signaling controls C/ebpa 
expression during hepatocyte maturation. 
The transcription factor Hnf4a is also critical for proper hepatocyte differentiation, 
morphology, and function. Although both hepatoblast and liver formation occurs normally 
in Hnf4a-/- embryos, hepatocyte differentiation is severely impaired. Several hepatic 
transcription factors are still expressed in Hnf4a-/- embryos, except for Hnf1a and 
pregnane-x-receptor, suggesting that Hnf4a is upstream of these factors in a signaling 
cascade that regulates hepatocyte differentiation (Li et al., 2000). Hnf4a-/- embryos, have 
a severe defect in the liver morphology and function. Hepatocytes from Hnf4a-/- embryos 
are small, round, and loosely connected in contrast to hepatocytes from wildtype 
embryos, which are large, flat, and have tight associations. Additionally, livers from 
Hnf4a-/- embryos fail to express genes associated with glucose metabolism, and do not 
express cell adhesion and cell junction molecules including E-cadherin and ZO-1 (Parviz 
et al., 2003). HNF4a occupies a majority of actively transcribed genes in adult 
hepatocytes, further demonstrating its significant role in regulating liver function (Odom 
et al., 2004). To study further its role in hepatocyte maturation, Hnf4a was deleted in 
mouse embryos after the liver specification stage. These embryos have reduced hepatic 
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gene transcription compared to wildtype embryos (Kyrmizi et al., 2006). Hnf4a is crucial 
for regulating hepatic gene expression, liver function, and epithelial morphogenesis 
during hepatocyte differentiation. The transcription factor Tbx3, also plays a role in 
maintaining the transcriptional regulatory network required for proper hepatoblast fate 
decisions. This is discussed in further detail in Section 1.5.3 of this thesis.  
The work done in model organisms to study liver development has been monumental in 
establishing protocols to differentiate pluripotent stem cells (PSCs) to hepatocytes. PSC-
derived hepatocytes are a powerful tool for studying human liver development and 
uncovering any human-specific differences that have been previously unknown. The 
evolution of hepatocyte differentiation protocols is discussed in Section 1.6.4 of this 
thesis. 
1.3.3 Pancreas development 
The pancreas is derived from two distinct regions of the foregut endoderm that bud off 
and come together. Pancreas development occurs in two stages, correlating with the 
appearance of endocrine cells. In the primary transition, a few glucagon and insulin 
positive cells appear early in development, while only endocrine cells appearing in the 
secondary transition contribute to the mature islet (Herrera, 2000). During primary 
transition, the pancreatic endoderm is induced, pancreatic multipotent progenitor cells 
(MPCs) undergo rapid proliferation and expansion between days E9.0-E12.5. Secondary 
transition begins around E13.5, where pancreatic epithelium forms a complex branched 
network that is segregated into different domains, and the MPCs differentiate to mature 
pancreatic cell types (Bastidas-Ponce et al., 2017; Pan and Wright, 2011).  
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Figure 1.5: Overview of pancreas development  
 
Figure 1.5: Overview of pancreas development 
Schematic summary of different stages of pancreas development.  
(A) Specification of dorsal pancreatic bud. The notochord secretes factors blocking sonic 
hedgehog signaling (Shh) in the adjacent dorsal pancreatic endoderm (purple), allowing 
for expression of pancreatic genes Pdx1, Ptf1a, Isl1, and Mnx1.  
(B) Epithelial pancreatic branches are segregated into the tip (blue) and trunk (purple) 
domains. Notch signaling promotes Nkx6.1 expression in trunk cells, while Notch 
inhibition allows expression of Ptf1a in tip cells.  
(C) Bipotential trunk cells differentiate to ductal cells (light purple) upon receiving Notch 
signals. Notch inhibition drives trunk cells to endocrine progenitors (green) which are 
characterized by Ngn3 expression. Endocrine progenitors then differentiate into the five 
endocrine cell types found in the pancreas: a-cells, b-cells, d-cells, PP- cells, and e-cells. 
(D) Endocrine cells (green) undergo epithelial-mesenchymal transition (EMT) and 
delaminate from the trunk into the surrounding mesenchyme. Differentiated endocrine 
cells receive various signals that facilitate aggregation to form Islets of Langerhans, the 
functional endocrine component of the pancreas. Adapted from Bastidas-Ponce et al., 





1.3.3.1 Dorsal and ventral pancreas specification  
The pancreas develops from two regions of the foregut endoderm to form the dorsal and 
ventral pancreatic buds. Pdx1 is considered a master regulator of pancreas 
development, as it is one of the earliest genes expressed in pancreatic endoderm. Pdx1 
expression is detected in the pancreatic epithelium around E8.5 (Ahlgren et al., 1996). 
Pdx1-/- embryos form a rudimentary dorsal pancreatic bud and no ventral bud. However, 
the bud fails to expand and these mice do not form a pancreas (Jonsson et al., 1994; 
Offield et al., 1996). A small number of insulin- and glucagon-producing cells are 
detected in Pdx1-/- embryos. However these embryos have far fewer insulin and 
glucagon positive cells than wildtype mice (Ahlgren et al., 1996). Lineage tracing studies 
show that multipotent progenitor cells (MPCs) expressing Pdx1 give rise to all three 
pancreatic lineages (Gu et al., 2002). These findings suggest Pdx1 is needed for ventral 
but not dorsal pancreatic induction, and is required for subsequent growth, 
differentiation, and maturation of MPCs.  
Ptf1a is also important in early pancreas development. Ptf1a expression is detected in 
the pancreatic epithelium at E9.5, and Ptf1a positive cells give rise to all duct, acinar, 
and pancreatic endocrine cells (Kawaguchi et al., 2002). Similar to Pdx1 null embryos, 
Ptf1a-/- embryos form a rudimentary dorsal pancreatic bud and no ventral bud. Ptf1a also 
acts in fate determination, as cells that should become pancreatic cells adopt a 
duodenum fate in Ptf1a-/- embryos (Kawaguchi et al., 2002). Additionally, Ptf1a-/- mice fail 
to develop pancreatic exocrine cells, and have fewer pancreatic endocrine cells which 
are mislocalized to the spleen (Krapp et al., 1998). These studies demonstrate that Ptf1a 
is important at both specification of the ventral bud, and later in pancreas development. 
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Two transcription factors that are important for dorsal bud formation are Mnx1 and Isl1. 
Embryos lacking Mnx1 do not form a dorsal pancreatic bud, while the ventral pancreatic 
bud appears largely normal. Mnx1-/-- embryos have small pancreatic islets, with fewer b-
cells that are less functional compared to wildtype embryos (Harrison et al., 1999; Li et 
al., 1999). Similarly, Isl1-/- embryos lack a dorsal pancreatic bud, with little effect on 
ventral pancreas development. These embryos completely fail to develop islets (Ahlgren 
et al., 1997). These finding reveal involvement of different transcription factors in dorsal 
and ventral bud specification, and yet again demonstrate that transcription factors have 
multiple roles in different stages of pancreatic development. 
Signaling pathways also play a critical role in early pancreatic specification. The dorsal 
and ventral pancreatic epithelium have different surrounding tissues, thus receive 
different specification signals to induce bud formation. At E8.5, the dorsal pancreatic 
endoderm lies in close proximity to the notochord. The notochord expresses Activin-βB 
and FGF2, which suppress Sonic hedgehog (Shh) signaling in the dorsal pancreatic 
endoderm and allow for Pdx1 expression. (Hebrok et al., 1998; Kim et al., 1997) (Figure 
1.5A). Retinoic acid (RA) is also critical for dorsal pancreatic development. In Xenopus, 
RA blocks Shh signaling in the pancreatic endoderm, and is needed for further 
pancreatic development (Chen et al., 2004). Additionally, mice lacking retinaldehyde 
dehydrogenase 2, which is involved in RA synthesis, do not express Pdx1 in the 
pancreatic endoderm, and do not form a dorsal pancreatic bud (Martín et al., 2005; 
Molotkov et al., 2005).  At E9.0 in the mouse, the dorsal aorta fuse and displace the 
notochord, putting the dorsal pancreatic endoderm in direct contact with endothelial 
cells. Endothelial cells secrete signals that induce Pdx1 expression in the dorsal 
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pancreatic endoderm, and Insulin, NeuroD, and Pax6 later in endocrine pancreas 
differentiation (Lammert et al., 2001).  
The ventral pancreatic bud develops from the lateral domains of the ventral foregut 
endoderm, which also gives rise to the liver, extrahepatic bile ducts (Tremblay and Zaret, 
2005). As described in Section 1.3.2.1, the ventral foregut endoderm lies is close 
proximity to the cardiac mesoderm and septum transversum mesenchyme, which 
secrete FGF and BMP signals, respectively, to specify the liver. The region of ventral 
foregut endoderm that do not receive these signals becomes ventral pancreatic bud 
(Deutsch et al., 2001; Rossi et al., 2001). The molecular mechanisms distinguishing liver 
versus ventral pancreas development are discussed in greater detail in Section 1.4 of 
this thesis. Additionally, multipotent progenitors expressing both Pdx1 and Sox17 are 
present in the ventral foregut endoderm. The Notch effector Hes1 downregulates Sox17 
in a subset of these cells, permitting Pdx1 expression, and therefore development of the 
ventral pancreas (Spence et al., 2009). Interestingly, Hes1-/- embryos form ectopic 
pancreatic tissue (Sumazaki et al., 2004), suggesting that Hes1 regulates ventral 
pancreatic bud development by preventing a biliary fate through repression of Sox17.  
1.3.3.2 Pancreatic multipotent progenitor cell expansion  
As the dorsal and ventral pancreatic endoderm are specified, they thicken and evaginate 
into the surrounding mesenchyme, forming the pancreatic buds. Both pancreatic buds 
are comprised of multipotent pancreatic progenitors (MPCs). The ventral bud rotates, 
coming into contact with the dorsal bud, and the two buds fuse to form the pancreas 
(Slack, 1995). The buds undergo a complex series of morphological changes to form the 
highly branched pancreatic duct epithelium (Villasenor et al., 2010). This transient stage 
allows MPCs to proliferate and generate a sufficient progenitor pool, which is critical for 
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appropriate size of the final pancreas organ (Stanger et al., 2007). In addition to their 
role in pancreas specification and fate determination, Pdx1 and Ptf1a are also important 
for maintaining MPC identity (Burlison et al., 2008). The transcription factor Sox9 also 
marks MPCs. Sox9 maintains the MPC pool by regulating proliferation and keeping 
MPCs in an undifferentiated state (Seymour et al., 2007). Additionally, Sox9 directly 
regulates the expression of the transcription factors Hnf1b, Hnf6, and Foxa2, which 
maintain MPC identity (Lynn et al., 2007). These transcription factors are crucial for 
generating and maintaining the MPC pool. 
Additionally, Fgf10 signaling controls proliferation and the size of the MPC pool during 
branching morphogenesis. Fgf10-/- embryos form pancreatic buds, but they do not grow 
or undergo  differentiation and subsequent branching (Bhushan et al., 2001). Fgf10 
regulates MPC expansion by inducing Notch signaling to keep MPCs in an 
undifferentiated state (Hart et al., 2003; Norgaard et al., 2003). Mice lacking Hes1, a 
downstream effector of Notch, have fewer MPCs, leading to accelerated endocrine 
differentiation and pancreatic hypoplasia (Jensen et al., 2000a). Additionally, 
overexpression of Notch inhibits both exocrine and endocrine development, suggesting 
that this pathway is important for preventing MPC differentiation (Hald et al., 2003; 
Murtaugh et al., 2003). Notch signaling is key for maintaining MPC identity and 
generating the MPC pool. 
1.3.3.3 Pancreatic trunk versus tip differentiation  
At E11.5, pancreatic epithelium is divided into two domains: the tip domain which gives 
rise to acinar cells, and the trunk domain which gives rise to endocrine and ductal cells 
(Bastidas-Ponce et al., 2017). The Nkx6 factors (Nkx6.1 and Nkx6.2) and Ptf1a play an 
antagonistic role in segregating these domains. Nkx6.1 expression is to restricted to the 
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trunk while Ptf1a is in the tip (Figure 1.5B). Loss of Nkx6 factors results in Ptf1a 
expression in the trunk domain, and in an endocrine-to-acinar cell fate switch (Schaffer 
et al., 2010). Conversely, loss of Ptf1a results in an acinar-to-endocrine fate switch 
(Dong et al., 2008). The expression of Nkx6.1 in the trunk and Ptf1a in the tip is 
regulated by Notch signaling (Figure 1.5B). Notch drives Nkx6.1 expression in trunk 
MPCs to prevent an acinar fate (Afelik et al., 2012). Additionally, Notch represses Ptf1a 
expression, and loss of Notch signaling enhances pancreatic exocrine cell differentiation 
(Esni et al., 2004). Finally, several studies (Apelqvist et al., 1999; Jensen et al., 2000a) 
implicate Notch signaling in determining an endocrine versus exocrine fate, 
demonstrating another crucial role for this pathway in pancreas development. 
1.3.3.4 Endocrine specification  
Trunk cells contain bipotential progenitors that give rise to pancreatic endocrine or ductal 
cells (Figure 1.5C). Neurogenin3 (Ngn3) is a marker of endocrine progenitors (Apelqvist 
et al., 1999; Jensen et al., 2000b). Lineage tracing experiments reveal that Ngn3+ cells 
give rise to all endocrine cells but not ductal cells (Gu et al., 2002). Ngn3 expression 
occurs in two distinct phases, the timing of which correlates with the onset of the primary 
and secondary phases of endocrine development (Villasenor et al., 2008). Additionally, 
Ngn3 controls expression of endocrine-specific genes Isl1, Pax4, Pax6, and NeuroD 
(Gradwohl et al., 2000). Ngn3-/- mice do not have pancreatic endocrine cells (Gradwohl 
et al., 2000), and expression of Ngn3 under the Pdx1 promoter leads to ectopic 
formation of endocrine cells (Schwitzgebel et al., 2000). Up to this point in pancreas 
development, the Notch pathway has favored an endocrine fate. However, during 
endocrine specification, Notch signaling plays an inhibitory role and promotes a ductal 
cell fate (Qu et al., 2013) in part by regulating expression levels of the ductal cell marker 
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Sox9 (Shih et al., 2012). Notch represses Ngn3 via Hes1 to prevent an endocrine fate 
(Lee et al., 2001). Additionally, disrupting the Notch pathway results in increased Ngn3 
expression and enhanced endocrine differentiation (Apelqvist et al., 1999).  The 
relationship between Notch signaling and Ngn3 expression is critical for proper 
endocrine specification. 
1.3.3.5 Endocrine cell differentiation  
After endocrine specification, transcription factors specific to different endocrine lineages 
are expressed, driving differentiation to different islet cell types (Figure 1.5C). As 
development progresses, Pdx1 and Nkx6.1 become increasingly restricted to b-cells. 
Pdx1 maintains b-cell function and identity. Loss of Pdx1 leads to a decrease in insulin-
positive cells and attenuated b- cell specific gene expression (Ahlgren et al., 1998). 
Additionally, Pdx1 regulates b-cell proliferation, which is required to generate the 
appropriate number of b-cells in islets (Gannon et al., 2008). Nkx6.1 also plays a critical 
role in b-cell development. Nkx6.1-/- mice have fewer b-cell precursors and no b-cell 
differentiation (Sander et al., 2000). Nkx6.1 specifies b-cells prior to Ngn3 expression 
(Nelson et al., 2007). Finally, Nkx6.1 drives b-cell proliferation and regulates the glucose 
responsiveness function of  b-cells (Schisler et al., 2008). These studies show that both 
Pdx1 and Nkx6.1 have important roles in multiple stages of pancreas development, 
particularly during b-cell maturation. 
Additionally, Pax4 is needed for b- and d- cell differentiation, while Arx is required for a-
cell differentiation. The balance between levels of these transcription factors is key in 
regulating endocrine fates. Pax4-/- mice have more a-cells and fewer b- and d-cells 
(Sosa-Pineda et al., 1997). Conversely, Arx-/- mice have more b- and d-cells and fewer 
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a-cells. (Collombat et al., 2003) Finally, Pax4 and Arx double knockout mice have 
significant increase in the number of d-cells (Collombat et al., 2005). Pax4 and Arx 
negatively regulate each other (Collombat et al., 2003) to maintain the proper levels for 
normal differentiation of these endocrine cell types.  
Another transcription factor that regulates endocrine lineage specification is Nkx2.2. 
Nkx2.2 is first expressed in the pancreatic epithelium in early development, and then 
later becomes restricted to the endocrine lineage (Sussel et al., 1998). Nkx2.2-/- embryos 
do not have b-cells, and have fewer a- and PP-cells. Although islets exist in these 
embryos, none of the endocrine hormones are produced and Nkx2.2-/- mice are 
hyperglycemic (Sussel et al., 1998). Additionally, the loss of Nkx2.2 results in the 
expansion of e-cell population and a reduced number of b-cells (Prado et al., 2004). 
Nkx2.2 is also upstream of Nk6.1 (Sander et al., 2000), and directly represses Arx 
(Papizan et al., 2011), thus promotes a b-cell over a-cell fate. These studies 
demonstrate that Nkx2.2 is required for both proper differentiation and function of b-cells.  
Once lineage specification occurs, transcription factors MafA and MafB are responsible 
for a- and b-cell maturation. MafB is expressed in immature a- and b-cells (Artner et al., 
2006) and needed for b-cell maturation (Artner et al., 2007). As the cells mature, MafB 
becomes restricted to a-cells and is needed for proper a-cell function (Artner et al., 
2006). Mature b-cells make the switch from MafB to MafA expression (Nishimura et al., 
2006). Islet development is not affected in MafA-/- mice, but they do develop diabetes 
and have impaired glucose tolerance after birth, suggesting that MafA is more important 
for b-cell function rather than development (Zhang et al., 2005). The balance between 
these two factors is key in distinguishing between and a- and b-cell fate.  
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1.3.3.6 Islet formation and maturation 
Once endocrine cells have differentiated, they delaminate from the pancreatic trunk 
epithelium and migrate into the surrounding mesenchyme. Though the exact mechanism 
of how the delamination occurs remains unknown, there is strong evidence that it occurs 
through an epithelial-to-mesenchymal transition (EMT) (Figure 1.5D). EMT is 
characterized by loss of cell polarity and adhesion, and changes in cytoskeletal 
structure. Snail2, a potent inducer of EMT, is detected in Ngn3-positive cells, suggesting 
EMT is initiated shortly after endocrine specification. Additionally, E-cadherin, and 
epithelial marker, expression is lost while N-cadherin, a mesenchymal marker, is 
upregulated in cells just outside the pancreatic epithelium. The change from E- to N-
cadherin is a hallmark of EMT, and correlates with Snail2 expression, suggesting that it 
may be involved in this transition (Rukstalis and Habener, 2007). Cells emerging from 
the trunk epithelium take on the characteristic shape of cells undergoing EMT, and 
express markers, such as Vimentin and Snail family transcription factors, associated 
with mesenchymal cells (Cole et al., 2009). Ngn3 may be responsible for triggering EMT 
and delamination of endocrine cells from the trunk epithelium. Upon Ngn3 expression, 
cells being losing polarity, down regulate E-cadherin, break down the basal lamina, and 
delaminate into the mesenchyme. Additionally these cells express mesenchymal 
markers Vimentin and N-cadherin, and Ngn3 controls Snail2 expression in the pancreas 
(Gouzi et al., 2011). Taken together, these studies provide compelling evidence that 
endocrine cells undergo EMT while delaminating from the trunk epithelium. 
After endocrine cells delaminate from the trunk epithelium, they migrate into the 
surrounding mesenchyme and cluster together to form pancreatic islets. The mechanism 
of how these cells find each other and aggregate remains unclear. Integrins mediate 
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pancreatic endocrine cell migration. Inhibiting specific integrins prevents endocrine cell 
emergence from the trunk (Cirulli et al., 2000), and migration after delamination (Yebra 
et al., 2003). The GTPase Rac1 mediates endocrine islet migration by regulating E-
cadherin expression and cell spreading. Blocking Rac1 results in increased E-cadherin 
levels, and impaired actin remodeling in endocrine cells (Greiner et al., 2009). Cell 
adhesion molecules have also been implicated in aggregation during islet assembly. 
Disrupting E-cadherin expression in b-cells prevents them from properly integrating into 
islet structures (Dahl et al., 1996). Additionally, the cell adhesion molecule N-CAM is 
required for proper endocrine cell positioning within the islet, as loss of N-CAM results in 
mislocalization of a-cells in developing islets (Esni et al., 1999). Interactions between the 
islets and surrounding endothelial cells and neurons also influences islet structure and 
function (Bastidas-Ponce et al., 2017). b-cells continue to mature and become fully 
functional postnatally.  
1.3.3.7 Differences in human pancreas development 
Most of our knowledge of pancreas development is based on studies done in model 
organisms. Studies done on pancreas development in human embryos (Jeon et al., 
2009; Lyttle et al., 2008; Piper et al., 2004) reveal similarities and differences between 
the two species. While the timing of some transcription factors is slightly delayed in 
humans compared to mouse development, the expression occurs in the same general 
chronological and spatial patterns (Jennings et al., 2015). For example, in the mouse, 
Pdx1 expression is first detected when the dorsal pancreatic endoderm is adjacent to the 
notochord (Kim et al., 1997). However, in humans, PDX1 expression is not detected until 
the gut tube has closed and the dorsal pancreatic is no longer near the notochord and 
dorsal aorta (Jennings et al., 2013). One major difference between human and mouse 
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development is that endocrine cells are produced in a single stage in humans rather 
than in two distinct waves as seen in the mouse (Jennings et al., 2013).  Another 
significant difference is that NKX2.2 is not detected until after endocrine specification 
(Jennings et al., 2013), while in the mouse it is first detected during bud formation 
(Sussel et al., 1998). Finally, the mature islet architecture differs between mice and 
humans. In the mouse, b-cells make up the majority (75%) of the islet and are 
concentrated in the center, with the other endocrine cells surrounding them. In humans, 
b-cells represent about 50% of the islet, and the different endocrine cell types are 
distributed homogenously throughout the islet (Brissova et al., 2005). These 
observations note that while the most steps of pancreas development are similar 
between species, there are some human-specific differences. Studying these differences 
can provide insight into human b-cell biology, which can be applied improving generation 
of pluripotent stem cell derived b-cells for use in a therapeutic context.  
1.4 Liver versus pancreas development 
The liver and pancreas are closely related and develop from the same region of the 
endoderm. This thesis explores the potential role of the transcription factor TBX3 in 
endoderm patterning and distinguishing between a liver and pancreas fate. Next, we will 
discuss what is known about liver versus pancreas development.  
The liver and ventral pancreas both develop from the lateral endoderm of the ventral 
foregut. Within the lateral endoderm, the ventral pancreatic endoderm domain lies 
caudal to the hepatic domain (Tremblay and Zaret, 2005). The transcription factor Hex 
plays a role in establishing the liver and ventral pancreas domains in the foregut 
endoderm by controlling the proliferation and positioning of the ventral foregut endoderm 
(Figure 1.6A). Ventral pancreas specification fails in Hex-/- embryos because the  
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Figure 1.6: Liver versus ventral pancreas specification 
 
 
Figure 1.6: Liver versus ventral pancreas specification 
The liver and the ventral pancreas develop from the same part of the ventral foregut 
endoderm.  
(A) The transcription factor Hex controls proliferation and positioning of the ventral 
foregut endoderm past the cardiac mesoderm.  
(B) The cardiac mesoderm and septum transversum mesenchyme (STM) secrete 
fibroblast growth factor (FGF) and bone morphogenetic protein (BMP) signals, 
respectively, to the neighboring ventral foregut endoderm to specify the hepatic 
endoderm (red), that expresses liver-specific genes Albumin, Afp, and Ttr. BMP signals 
prevent expression of pancreatic genes Pdx1 and Ptf1a in the hepatic endoderm. These 
genes are expressed in the cells do not receive FGF signals from the cardiac mesoderm 
to specify the ventral pancreatic epithelium (purple). Adapted from Bort et al., 2004. 




endoderm is not positioned beyond the cardiac mesoderm, thus all cells receive FGF 
signals and are specified to liver (Bort et al., 2004). In wildtype embryos, Pdx1 is 
expressed in the ventral endoderm that extends past the cardiac mesoderm, and this 
region becomes the ventral pancreatic bud. Since the endoderm is not positioned 
correctly in Hex-/- embryos, ventral pancreatic bud does not form. Explant studies using 
Hex-/- ventral foregut endoderm show that it is still competent to induce pancreatic gene 
expression (Bort et al., 2004). This provides evidence that ventral foregut endoderm 
cells can adopt either a liver or pancreas fate depending on their position in the 
developing embryo.  
The liver and ventral pancreas are both specified around the same time at E8.5. The 
region of the ventral foregut endoderm adjacent to the cardiac mesoderm expresses the 
hepatic gene Albumin while the region of the ventral endoderm extending past the 
cardiac mesoderm expresses Pdx1, demonstrating that there are distinct, non-
overlapping liver and pancreas domains (Deutsch et al., 2001) (Figure 1.6B). Ventral 
foregut explants from 2-6 somite embryos (prior to the onset of FGF signaling and 
hepatic specification) express pancreatic genes including Pdx1, Ptf1a, and Isl1. When 
these explants are cultured with FGF or cardiac mesoderm, pancreatic genes are no 
longer present while Albumin is strongly expressed, suggesting that pancreas is the 
default fate of the ventral foregut endoderm (Deutsch et al., 2001). The cardiac 
mesoderm induces a hepatic fate in the ventral foregut directly next to it, while the 
section of the ventral foregut that extends past the cardiac mesoderm escapes 
repressive FGF signals and develops into the ventral pancreas. 
BMP signaling also plays a role in patterning the liver versus pancreatic domains in the 
ventral foregut endoderm. BMP signals are required for liver induction. When BMP 
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signaling is blocked, Pdx1 expression is activated at the expense of Albumin expression 
in the ventral foregut  (Rossi et al., 2001). BMP signals make cells competent to receive 
FGF signals that induce a hepatic fate and exclude a pancreatic fate. Overexpressing 
Bmp2b in zebrafish results in cells that normally contribute to the ventral pancreas to 
adopt a liver fate instead (Chung et al., 2008), providing further evidence that BMP 
signaling promotes hepatic specification by suppressing a pancreatic fate.  
Patterning and specification of the liver and ventral pancreas is a tightly regulated 
process. Hex controls proliferation and proper positioning of the ventral foregut 
endoderm. This ensures that the presumptive hepatic endoderm receives FGF and BMP 
signals to become the liver, while the ventral pancreas endoderm escapes these signals 
and develops into the ventral pancreatic bud. Further studies into transcription factors 
and signals that segregate the liver and ventral pancreas domains will not only enhance 
our knowledge of endoderm patterning, but can also help refine differentiation protocols 
to generate functionally mature hepatocytes and b-cells from pluripotent stem cells.  
1.5 Characteristics of TBX3 
TBX3 is a transcription factor that has many roles in development and disease. In 
particular, Tbx3 has been well-studied during mouse liver development. However, there 
have been instances in which development in the mouse differs from human 
development. One goal of this thesis is to determine whether TBX3 functions similarly in 
mouse and human liver development. Additionally, this thesis examines the role of TBX3 
in distinguishing hepatic versus pancreatic domains during foregut endoderm patterning, 
and the role of TBX3 in pancreatic differentiation from pluripotent stem cells. Here we 
discuss the various functions of TBX3.  
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1.5.1 Structure of TBX3 
TBX3 is a member of the T-box family of transcription factors, which is involved in many 
developmental processes. T-box transcription factors are characterized by the highly 
conserved T-box DNA binding domain, which is 180-200 amino acids in length and 
contains the consensus half site 5’-AGGTGTGAAA-3’, known as the T-box binding 
element (Papaioannou, 2014). The T-box family is divided into five subfamilies: T, Tbx1, 
Tbx2, Tbx6, and Tbr1. Tbx3 is a member of the Tbx2 subfamily, along with Tbx2, Tbx4, 
and Tbx5 (Naiche et al., 2005). In particular, Tbx3 and Tbx2 have highly similar 
sequences and have similar functions in development (Gibson-Brown et al., 1998; 
Lüdtke et al., 2016; Singh et al., 2012; Zirzow et al., 2009). There is some degree of 
redundancy between Tbx2 and Tbx3, but this is dependent on biological context. 
TBX3 is located on chromosome 12, has seven exons, and is 723 amino acids in length. 
The T-box domain is located in exons 1-4 (Khan et al., 2020). An isoform with an 
additional 20 amino acids in the T-box domain, termed TBX3+2a, has been identified 
(Figure 1.7A). Whether or not these isoforms have similar or distinct functions remains 
contested (Fan et al., 2004; Hoogaars et al., 2008). TBX3 has two repression domains: 
one is within the T-box DNA binding domain (amino acids 123-300) and the second is at 
the C-terminal end (amino acids 567-623), the latter being the dominant repression 
domain (Carlson et al., 2001; Khan et al., 2020). TBX3 also has an activation 
domain(amino acids 423-500), however it appears that TBX3 acts primarily as a 
repressor (Carlson et al., 2001) (Figure 1.7B).  
The crystal structure of TBX3 protein has been identified. The structure of the T-box 
domain is similar to that of Xbra, the Xenopus homolog of Brachyury, which had been 
previously crystallized. However, TBX3 binds differently to DNA than Xbra does. T-box  
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Figure 1.7: Structure and function of TBX3 
 
Figure 1.7: Structure and function of TBX3 
(A) TBX3 is located on chromosome 12 and has 7 exons. The T-box DNA binding 
domain is located in exons 1-4. An isoform with an extra 60 bp encoding exon 2a exits, 
but its function remains controversial.  
(B) The TBX3 protein is 723 amino acids long. The T-box DNA binding domain is 
represented in the magenta boxes. TBX3 has one activation domain (orange box), and 
two repression domains (green boxes), with the C-terminal repression domain being 
dominant.  
(C) In mouse liver development, Tbx3 is expressed in the hepatoblasts and maintains 
expression of Hnf4a and C/ebpa to promote a hepatocyte fate, and represses Hnf6 
expression to suppress a cholangiocyte fate. Adapted from Khan et al., 2020 and Zong 
and Stanger, 2012. Created with BioRender.com. 
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factors are thought to bind to the consensus half site as monomers, then dimerize to 
become fully functional. The crystal structure of the TBX3/DNA complex shows that 
TBX3 binds to consensus sequences but does not dimerize (Coll et al., 2002). This 
highlights differences in how members of the T-box family bind to DNA. 
1.5.2 Functions of TBX3 
Tbx3 is dynamically expressed during early development in mouse embryos, and drives 
mesendoderm differentiation as it correlates with markers T, EOMES, and SOX17 in 
Xenopus embryos (Weidgang et al., 2013). Additionally, it regulates EOMES expression 
and drives endoderm differentiation (Kartikasari et al., 2013). Tbx3 has also been 
detected in several tissues during development, including the heart, limbs, lungs, 
mammary gland (Douglas and Papaioannou, 2013; Gibson-Brown et al., 1998; Lüdtke et 
al., 2016; Singh et al., 2012). Tbx3 is also expressed in the developing liver, which is 
discussed in further detail in Section 1.5.3. Although Tbx3 expression has been 
observed in both the developing and adult pancreas in mice, its function has yet to be 
determined (Begum and Papaioannou, 2011; Zhou et al., 2007). In mouse embryos, 
Tbx3 expression is mainly restricted to the pancreatic mesenchyme surrounding the 
epithelial branches. The Tbx2 expression pattern generally overlaps with that of Tbx3 in 
embryos. In the adult mouse, Tbx2 is expressed in pancreatic islet while Tbx3 is 
restricted to exocrine tissue, suggesting a possible functional difference between the two 
transcription factors (Begum and Papaioannou, 2011). In human embryos, TBX3 is 
expressed in SOX9+/PTF1A+ tip progenitors that give rise to exocrine component of the 
pancreas (Villani et al., 2019), This differs from the mouse, as Tbx3 is not detected in 
any pancreatic progenitor cells, highlighting a potential species-specific difference 
between human and mouse. Additionally, neither TBX2 or TBX3 is expressed in adult 
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human b-cells. However, TBX2 and TBX3 expression are induced in both type 1 and 
type 2 diabetes, raising the possibility that they play a role in disease progression 
(Kaestner et al., 2019; Russell et al., 2019, https://hpap.pmacs.upenn.edu/). This is not 
seen in the mouse, further suggesting possible species-specific differences in TBX3 
expression and function during pancreas development and disease. 
In humans, TBX3 is implicated in Ulnar-Mammary Syndrome (UMS), a rare genetic 
disorder that causes defects in limb development, mammary and apocrine gland 
hypoplasia, and genital abnormalities. It is an autosomal dominant disorder caused by a 
wide variety of loss-of-function mutations in one allele of TBX3. These include missense, 
frameshift, and early truncation mutations. The specific mutation determines the severity 
of the phenotype in the patient (Bamshad et al., 1997, 1999). A mouse model was 
developed to further study UMS. However, unlike in humans, a UMS-like phenotype is 
only seen when there are mutations in both alleles of Tbx3, suggesting a possible 
difference in the requirement of TBX3 between species. Interestingly, yolk sac and liver 
defects are seen in Tbx3-/- mice (Davenport et al., 2003). This has not been observed in 
human with UMS, since there are no patients with homozygous mutations in TBX3.  
In addition to its roles in development, TBX3 acts as a cell cycle regulator in the p53 
pathway. p14ARF represses MDM2, resulting in increased levels of p53, which leads to 
cell cycle arrest. Disruption of this pathway leads to uncontrolled cell proliferation. TBX3 
directly represses CDKN2A, which encodes p14ARF (Carlson et al., 2002; Lingbeek et al., 
2002), Additionally, TBX3 directly suppresses p21, a downstream target of p53 that 
mediates cell cycle arrest (Willmer et al., 2016). TBX3 overexpression results in 
uncontrolled proliferation in several types of cancers including liver and breast cancers 
(Renard et al., 2007; Yarosh et al., 2008). Additionally, TBX3 overexpression promotes 
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tumor invasiveness and migration in breast cancer and melanoma by repressing E-
cadherin and promoting epithelial-to-mesenchymal transition (Krstic et al., 2016, 2019; 
Rodriguez et al., 2008). TBX3 contributes to tumor progression through many different 
mechanisms, highlighting its potential as a therapeutic target for treating cancer patients.  
Tbx3 is also important for mouse embryonic stem cells (mESC) maintenance.Tbx3 is 
expressed in mESCs, and is required to maintain self-renewal and pluripotency (Ivanova 
et al., 2006; Niwa et al., 2009; Russell et al., 2015). Additionally, Tbx3 enhances the 
quality of induced pluripotent stem cells from mouse fibroblasts (Han et al., 2010). 
Conversely, TBX3 is not expressed in human embryonic stem cells (hESCs), is not 
required for self-renewal and maintenance, and hESCs lacking TBX3 are still able to 
differentiate (Esmailpour and Huang, 2012). This difference in the role of TBX3 in 
mESCs and hESCs can be explained by pluripotent state. mESCs are thought to be in a 
naïve state, while human ESCs are in a primed state. This difference in pluripotency 
state calls for different culture conditions and gene expression patterns to maintain 
pluripotency in mESCs versus hESCs (Nichols and Smith, 2009). This includes Tbx3 
which is expressed in naïve mESCs but not primed hESCs (Davidson et al., 2015). This 
difference allowed us to utilize a human pluripotent stem cell system to generate viable 
TBX3 knockout cells and study the function of TBX3 during human liver development. 
1.5.3 TBX3 in liver development 
Tbx3 plays several roles during mouse liver development. Tbx3 is expressed in 
hepatoblasts, controls liver bud outgrowth, and regulates fate decisions later in 
development. Tbx3-/- embryos form small liver buds which do not develop into a 
functionally a mature liver. Additionally, the basement membrane does not degrade and 
hepatoblasts fail to migrate into the septum transversum mesenchyme. Hepatoblasts 
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from Tbx3-/- embryos have elevated levels of E-cadherin and laminin, and decreased 
expression of Prox1 in the liver bud (Lüdtke et al., 2009).  Tbx3-/- embryos display a 
similar phenotype to Prox1-/- embryos. As mentioned in Section 1.3.2.2, Prox1 is 
required for hepatoblast delamination and migration into the surrounding mesenchyme 
as the liver bud forms. These findings suggest that while Tbx3 is not required for hepatic 
specification, it is necessary for proper growth and progression of liver development, in 
part through maintenance of Prox1 expression (Lüdtke et al., 2009). Tbx3 is also critical 
for proper fate decisions during hepatoblast differentiation as it promotes a hepatocyte 
fate over a cholangiocyte fate. Tbx3 maintains expression of hepatic transcription factors 
Hnf4a and C/ebpa, while repressing Hnf6 which is important for cholangiocyte 
development (Figure 1.7C). In Tbx3-/- embryos there is a switch in the expression pattern 
of these transcription factors, with increased levels Hnf6 and its downstream target 
Hnf1b, and decreased Hnf4a and C/ebpa levels. Other hepatic markers including 
Albumin, AFP, aAT, and c-Met also have reduced expression in Tbx3-/- embryos, 
resulting in more cholangiocytes and fewer hepatocytes compared to their wildtype 
counterparts. Tbx3 negatively regulates the tumor suppressor p19ARF (Brummelkamp et 
al., 2002). Tbx3-/- embryos exhibit a significant reduction in proliferating hepatoblasts due 
to increased levels of p19Arf. Overexpressing p19ARF wildtype hepatoblasts results in 
decreased proliferation and expression of cholangiocyte markers Ck19 and Ck7, the 
same phenotype seen in hepatoblasts from Tbx3-/- embryos. Taken together, these 
results suggests Tbx3 controls hepatobiliary fate decisions of hepatoblasts by regulating 
proliferation via p19ARF (Suzuki et al., 2008). The role of Tbx3 in regulating hepatoblast 
delamination and fate decisions has been well-established in mice, but it is unclear 
whether TBX3 acts similarly in human liver development. To address this question, we 
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used pluripotent stem cells to study the function of TBX3 during this developmental 
process.  
1.6 Pluripotent stem cells 
Pluripotent stem cells (PSCs) are characterized by the ability to self-renew while 
maintaining an undifferentiated state, and have the capability to differentiate to all cell 
types of the body. PSCs include embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs), and serve as a valuable model system for studying human 
development, physiology, and disease. PSCs can also be used in drug discovery, and in 
cell-replacement therapies. This thesis utilizes PSCs to study the role of TBX3 in liver 
and pancreas development. We generated TBX3 knockout PSC lines and differentiated 
them to hepatocytes and pancreatic progenitors to study how the loss of TBX3 impacts 
these processes.  
1.6.1 Discovery of embryonic stem cells 
Embryonic stem cells (ESCs) are derived from the inner cell mass (ICM) of blastocyst 
stage embryos, which occurs prior to implantation, during development. The ICM 
consists of pluripotent stem cells that develop into the three germ layers (the ectoderm, 
mesoderm, and endoderm) and their derivatives. In 1981, two groups successfully 
isolated the ICM from mouse blastocysts and cultured them in vitro (Evans and 
Kaufman, 1981; Martin, 1981). These mouse ESCs (mESCs) can proliferate and be 
maintained on fibroblast feeder cells, and form embryoid bodies, teratomas, and 
germline competent chimeras (Ginis et al., 2004), confirming their pluripotent 
characteristics. The discovery of mESC provided a new platform to study development, 
as they could be easily differentiated to different cell types. Another advantage of 
mESCs is that they could be genetically manipulated to introduce specific mutations, 
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advancing the way we studied mammalian genetics. (Evans, 2011). The work done to 
identify and establish mESCs was a groundbreaking achievement in the field of 
developmental biology, and paved the way for the discovery and characterization of 
human ESCs.  
Human embryonic stem cells (hESCs) were first described in 1998 (Thomson et al., 
1998). Human embryos produced for in vitro fertilization were obtained at the cleavage 
stage and cultured to the blastocyst stage. The ICM population was removed from the 
blastocysts and cultured on fibroblast feeder cells for multiple passages without 
differentiating, while maintaining a normal karyotype. Like mESCs, hESCs form 
teratomas and can differentiate to all three germ layers. Prior to hESCs isolation and 
culture in vitro, studying human development was challenging. hESCs serve as a model 
system for uncovering attributes of development specific to humans that could not be 
understood using traditional model organisms. In addition to studying human 
development, hESC-derived cell types  can be used in disease modeling studies, and 
have the potential for use in cell-replacement therapies, making them a valuable tool for 
advancing disease treatments.  
1.6.2 Induced pluripotent stem cells  
The stem cell field experienced a major advancement with the advent of induced 
pluripotent stem cells (iPSCs). iPSCs helped bypass some disadvantages of using 
hESCs. First, they avoid any possible ethical controversies of using ESCs since they are 
derived from patients instead of embryos. Another advantage is that they provide a novel 
opportunity to use patient-derived cells to study specific mutations in development and 
disease progression. Additionally, since the patient’s own cells are used to generate 
iPSCs, they can avoid potential rejection if used in stem cell-based treatments. 
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There were several key findings that lead to the development of iPSCs. First, was 
somatic cell nuclear transfer, in which the nucleus from a differentiated somatic cell is 
transferred to an enucleated egg, which develops into an embryo or fully development 
organism. This was first demonstrated in Xenopus (Gurdon, 1962) and later in sheep 
(Wilmut et al., 1997), suggesting that terminally differentiated cells contain all the 
necessary information needed for development. Next, came the idea of a master 
regulator, in which certain transcription factors have the ability to convert cells to 
different fates. Expressing MyoD, which controls myogenesis, resulted in expression of 
muscle-specific genes in various non-muscle cell types  (Weintraub et al., 1989). 
These findings raised the question whether there were transcription factors that allowed 
for differentiated cells to be reprogrammed to a pluripotent state similar to ESCs. Mouse 
embryonic and adult fibroblasts were converted to iPSCs by expression of Oct4, Sox2, 
c-myc, Klf4 (Takahashi and Yamanaka, 2006). Soon after, human adult fibroblasts were 
reprogrammed to iPSCs with these same transcription factors (Takahashi et al., 2007). 
Interestingly, another group was able to reprogram human fibroblasts to iPSCs using a 
different set of factors (OCT4, SOX2, NANOG, and LIN28), demonstrating there are 
different combinations of factors than can reprogram cells (Yu et al., 2007). Both groups 
showed that iPSCs express pluripotent markers and can form teratomas, indicating they 
have properties similar to hESCs. The innovation of iPSC was a major breakthrough in 
the field.  
1.6.3. Pluripotent stem cells as a model system  
Both ESCs and iPSCs serve as powerful tools for studying development, physiology and 
disease. The knowledge gleaned about development from other model organisms has 
been used to develop protocols to differentiate PSCs to many cell types, including 
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neuronal cells, cardiomyocytes, hematopoietic cells, pancreatic b-cells, and hepatocytes. 
Using PSCs to study development can uncover species-specific differences and identify 
aspects of development unique to humans (Rowe and Daley, 2019). However, it has 
been difficult to generate functionally mature cell types from PSCs. Ongoing work by 
many groups has drastically improved these protocols over time, bringing us closer to 
PSC-derived cells that resemble cells found in vivo.    
PSCs are also an excellent tool for human disease modelling. They can be easily 
genetically manipulated using various technologies such as zinc finger nucleases (Zou 
et al., 2009), transcription activator-like effector nucleases (TALENs) (Hockemeyer et al., 
2011), or clustered regularly interspaced short palindromic repeats (CRISPR) (Maguire 
et al., 2019). Introducing specific mutations into genes of interest allows for study of both 
development and disease mechanism and progression. iPSCs from patients with a 
disease confer a particular advantage, as they already contain the mutation(s) of 
interest. The mutation can be corrected using gene editing, providing an isogenic 
wildtype control for disease modeling (Rowe and Daley, 2019).  PSCs also serve as a 
valuable tool for drug discovery. They can be differentiated to different cell types, on 
which large-scale drug screens can be performed. This is particularly advantageous for 
identifying compounds that may act as therapeutic agents when used in disease lines. 
Furthermore, studying the effects of these compounds on PSC-derived cell types can 
help elucidate the mechanism of various diseases (Shi et al., 2017). 
The ultimate goal is generating different cell types from PSCs that can be used in cell-
replacement therapies in patients. While this technology holds great promise, there are 
still some safety challenges in this area. First, is the concern of tumorigenicity of PSCs. 
PSCs can form teratomas and can accumulate mutations that confer a growth 
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advantage while in culture over many passages. It is imperative to make sure that there 
are no undifferentiated cells present in the cells being put into patients (Yamanaka, 
2020). Additionally, cells derived from ESCs may induce and immune response and 
result in rejection. iPSCs have an advantage in this regard since they are derived from 
the patient’s own cells and are less likely to be rejected by the body (Shi et al., 2017). 
Despite these issues, PSCs remain an increasingly promising avenue for use in clinical 
applications and treatments. 
1.6.4 Differentiation of PSCs to hepatocytes and pancreatic b-cells 
PSCs can be differentiated to all cell types of the body, including endodermal lineages 
such hepatocytes and pancreatic b-cells (Figure 1.8). The differentiation protocols that 
have been developed are based on developmental studies done in mice and other 
model organisms, helping us mirror the appropriate timing of signals during 
development.  
The general PSC hepatocyte differentiation protocol involves adding Activin to generate 
definitive endoderm (DE), FGF2 and BMP4 to induce hepatoblast specification, and 
HGF, OSM, and Dexamethasone for hepatocyte maturation (Ogawa et al., 2013; Si-
Tayeb et al., 2010; Takayama et al., 2012). At each stage of the protocol, the 
differentiating cells expressed appropriate markers (Sox17 at DE, HNF4a and AFP in 
hepatoblasts, and ALB in hepatocytes). Interestingly, the hepatocytes generated from 
these 2-dimensional (2D) based protocols resemble fetal hepatocytes rather than mature 
hepatocytes. Differentiating PSCs in a 3-dimensional (3D) culture system generates 
cells that are more similar to mature hepatocytes than those from in a 2D system (Luo et 
al., 2018). The aggregation of hepatocytes results in increased expression of  
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Figure 1.8 Differentiating PSCs to endodermal lineages 
 
 
Figure 1.8: Differentiating PSCs to endodermal lineages 
Generalized schematic of differentiation protocols to direct PSCs to endodermal 
lineages, such as hepatocytes and pancreatic b-cells. Activin mimics Nodal signaling to 
drive PSCs to mesendoderm. High activin generates definitive endoderm (DE). Adding 
FGF and BMP directs DE to hepatoblasts, then hepatocyte growth factor (HGF), 
Dexamethasone (Dex), and Oncostatin M (OSM) drive differentiation to hepatocytes. 
Adding cyclopamine, FGF, and retinoic acid (RA) to DE generates pancreatic endoderm. 
Adding more specialized molecules drives the cells to hormone-producing cells found in 
the pancreatic islets. Adapted from Zorn and Wells, 2009. Created with BioRender.com 
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cytochrome p450 enzymes (Ogawa et al., 2013) and improved albumin secretion 
(Gieseck et al., 2014) in the 3D differentiations. Although it is still difficult to generate 
fully functional hepatocytes from PSCs, differentiation protocols are continually 
improving and getting closer to the end goal of generating mature hepatocytes for use in 
therapies for liver disease and damage. 
There has been great interest in generating pancreatic b-cells from PSCs for potential 
use in treatment or drug discovery for diabetes. Protocols for b-cell differentiation were 
established based on knowledge of pancreatic development in other model organisms. 
Although the b-cells generated from PSCs was an immense advancement, initial 
protocols yielded b-cells that were poly-hormonal (expressed a combination of insulin 
and either glucagon or somatostatin) and did not secrete insulin in response to glucose 
stimulation (D’Amour et al., 2006; Nostro et al., 2011). hESC-derived pancreatic 
progenitors were able to produce functional b-cells when transplanted into mice and 
allowed to mature for 3-4 months (Kroon et al., 2008; Rezania et al., 2012), but up until 
this point functionally mature b-cells could not be generated in vitro. It was later found 
that hESC-derived pancreatic progenitors enriched for the transcription factor NKX6.1 
generated mature b-cells upon transplantation into mice (Rezania et al., 2013). 
Differentiation protocols were modified to allow for NKX6.1 enrichment in pancreatic 
progenitors (Nostro et al., 2015). In 2014, two groups published in vitro protocols in 
which PSCs were successfully differentiated to mono-hormonal insulin expressing b-like 
cells that secreted insulin in response to glucose (Pagliuca et al., 2014; Rezania et al., 
2014). Additionally, upon transplantation of PSC derived b-like cells into mice, insulin 
was detected just two weeks later, and they were able to reverse diabetes in the mice. 
While these protocols greatly advanced the field, there is still room for improvement, 
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particularly in increasing yield of b-cells. The ability to generate b-cells from PSCs is not 
only monumental for studying b-cell biology, but is also immensely promising for 
identifying and developing diabetic drugs, and can potentially be used in therapeutic 
context for diabetes treatment. 
1.7 Overview of research goals 
The role of Tbx3 in liver development has been well established in mouse models. Tbx3 
regulates hepatoblast delamination and migration during liver bud formation. 
Additionally, Tbx3 influences hepatoblast fate decisions by promoting a hepatocyte fate 
over a cholangiocyte fate. To date, it is unclear whether TBX3 functions similarly during 
human liver development. We utilized human pluripotent stem cells and established 
hepatocyte differentiation protocols to address this question. We generated TBX3 
knockout PSC lines using CRISPR/Cas9 genome editing technology. We hypothesized 
that the TBX3 mutant PSCs would differentiate to hepatocytes less efficiently than 
wildtype PSCs, indicating that TBX3 acts similarly in mouse and human liver 
development. During the hepatocyte differentiations, we made a surprising observation 
that TBX3 mutant lines express pancreas-specific genes. This finding raised new 
questions of whether TBX3 distinguishes between liver and pancreas domains during 
endoderm patterning, and whether the loss of TBX3 impacts pancreatic differentiation. 
Chapter 2 of this thesis outlines generation of TBX3 mutant lines and relevant 
methodology to study TBX3 in liver and pancreas differentiation. Chapter 3 discusses 
how TBX3 impacts hepatocyte differentiation and pancreatic progenitor generation from 
PSCs, and highlights a potential mechanism for how TBX3 acts in these developmental 
findings. Finally, Chapter 4 discusses conclusions, potential impacts and implications 
from these studies.  
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Pluripotent stem cell culture and maintenance 
PSCs were cultured in an environment of 5% CO2, 5% O2, and 90% N2 on 0.1% gelatin 
(Sigma) and irradiated mouse embryonic fibroblasts. They were grown in human 
embryonic stem cell (hESC) medium consisting of DMEM/F12 (Corning) with 15% 
Knockout Serum Replacement (Gibco), 2mM L-glutamine (Corning), 1x Non-Essential 
Amino Acids (Gibco), 1x Penicillin/Streptomycin (Corning), 0.1 mM 2 b-mercaptoethanol 
(Gibco), and 10 ng/mL bFGF (R&D Systems). Medium was changed daily. PSCs were 
grown to 80% confluency and split at a 1:12 ratio using TryplE (Gibco) dissociation 
regent. Cells were replated in hESC medium with 5µM ROCK inhibitor Y-27632 
dihydrochloride (Tocris). 
2.2 Generation of TBX3 mutant lines using CRISPR/Cas9 genome editing 
TBX3 mutant PSC lines were generated, as described previously (Maguire et al., 2019). 
Briefly, two guide RNAs were designed to create a deletion in the endogenous TBX3 
locus. TBX3 gRNA1, 5'-GGAGTGGATGAGCCTCTCC-3', targeted the transcription site 
and TBX3 gRNA2, 5'-CAAAGGTAAACCATGTCAC-3', targeted the boundary of exon 5 
and intron 4 of the TBX3 locus. The gRNAs were cloned into the gRNA_Cloning Vector 
(Addgene no. 41824). 0.5 µg of each plasmid with the gRNA, and 1 µg of pCas9_GFP 
vector (Addgene no. 44719) were transfected into one well of a 6-well plate containing 
3.5 x 105 cells. Cells were sorted using a BD FACSAria II (Becton Dickinson) cell sorted 
and plated at a single cell density on 10 cm tissue culture dishes coated with 1:3 
Matrigel (Corning) and supplemented with mouse embryonic fibroblasts. Single colonies 
were picked, with half being cultured for expansion, and the other half screened for the 
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deletion by PCR and TOPO cloning (Thermo Fisher Scientific). Clones containing the 
deletion were then sequenced for confirmation. All gRNA, screening, and sequencing 
primer sequences can be found in Table 2.1.  
Table 2.1 Primers sequences utilized in generation of TBX3 mutant PSC lines  
Primer Sequence 
TBX3 ATG gRNA1 5'-GGAGTGGATGAGCCTCTCC-3' 
TBX3 intron-exon gRNA2 5'-CAAAGGTAAACCATGTCAC-3' 
TBX3 Deletion Screening  
F: 5'-CCTGTTAAAGCCGGGTCTAGCAC-3’ 
R: 5'-ATCTTGTCCACTCCTCACCCAC-3' 
TBX3 Wildtype allele 
Screening  
F: 5'-AACACAGCAGCTGCGGACTTG-3’  
R: 5'-ATCCATGATCGGCTTGGCC-3' 
TBX3 Deletion Sequencing 5'-GTGCATTAGTTGTGATTTCTGCCTCC-3' 
 
2.3 Hepatocyte differentiation  
The hepatocyte differentiation protocol previously described (Ogawa et al., 2013) was 
modified as follows. PSCs were split onto 1:3 Matrigel (Corning) coated 6-well plates 
and cultured until they reached 80-90% confluency before starting Day 0 of the 
differentiation. Cells were differentiated as a monolayer in 5% O2, 5% CO2, and 90% N2. 
Cells were cultured for 24 hours (Day 0) in RPMI medium (Corning) with 2mM L-
glutamine, 50 µg/ml stabilized ascorbic acid (SAA) (Wako), 4.5×10−4 M MTG (Sigma), 
100ng/mL Activin A (R&D Systems), and 2µM CHIR (Tocris). Cells were then cultured 
for 24 hours (Day 1) in RPMI medium with 2mM L-glutamine, 50 µg/ml SAA, 4.5×10−4 M 
MTG, 100ng/mL Activin A, and 5 ng/mL bFGF (R&D Systems). From Days 2-6, cells 
were cultured serum free differentiation (SFD) medium, with 2mM L-glutamine, 50 µg/ml 
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SAA, 4.5×10−4 M MTG, 100ng/mL Activin A, and 5 ng/mL bFGF. SFD medium consists 
of Iscove’s DMEM (Corning) supplemented with 25% Ham’s/F12 (Corning), 0.5% N2 
supplement (Gibco), 1% B27 without retinoic acid (RA) supplement (Gibco), and 1% 
bovine serum albumin (BSA) (Sigma). At Day 6, purity of the definitive endoderm (DE) 
was assessed by flow cytometry with DE being 95-98% CXCR4+/C-kit+. Cells were then 
dissociated using TryplE for 2 minutes and replated with ROCK inhibitor (Tocris) onto 
1:3 Matrigel coated 6-well plates at a density of 3.5 x 105 cells per well. On Day 7, the 
medium was replaced with hepatoblast specification medium consisting of H16 base 
medium supplemented 2mM L-glutamine, 50 µg/ml SAA, 4.5×10−4 M MTG, 40 ng/mL 
bFGF, and 50 ng/mL BMP4 (R&D Systems). H16 base medium consists of DMEM Low 
glucose (Gibco) supplemented with 25% Ham’s/F12, 1% B27 with RA (Gibco), and 1% 
BSA. Medium was changed every other day. On Day 13 medium was replaced with 
hepatocyte maturation medium A consisting of H16 base medium supplemented with 
2mM L-glutamine, 50 µg/ml SAA, 4.5×10−4 M MTG, 20 ng/mL Hepatocyte Growth Factor 
(HGF) (R&D Systems), 20 ng/mL Oncostatin-M (OSM) (R&D Systems), and 40 ng/ml 
dexamethasone (Dex) (Sigma). Medium was changed every other day. On Day 21, cells 
were transferred to an environment of 20% O2 and 5% CO2, and 90% N2. Medium was 
replaced with hepatoblast maturation medium B consisting of H21 medium 
supplemented with 2mM L-glutamine, 50 µg/ml SAA, 4.5×10−4 M MTG, 20 ng/mL HGF, 
20 ng/mL OSM, and 40 ng/mL Dex. H21 medium is the same as H16 except using 
DMEM high glucose (Gibco) as the base medium. Medium was changed every other day 
until Day 25. Cells were harvested on Day 0, Day 6, Day 9, Day 12, Day 15, Day 18, 




2.4 Pancreatic b-cell Differentiation  
The pancreatic b-cell differentiation protocol previously described (Rezania et al., 2014) 
was modified as follows. PSCs were split onto 1:30 Matrigel coated 6-well plates and 
cultured until they reached 80-90% confluency before starting Day 0 of the 
differentiation. Cells were grown in 20% O2 and 5% CO2, and 90% N2, and differentiated 
as a monolayer, Cells were cultured for 24 hours in RPMI medium with 100ng/mL Activin 
A, and 3µM CHIR (Day 0). Cells were cultured for another 24 hours (Day 1) in RPMI 
medium with 100 ng/mL Activin A, 0.3 µM CHIR, and 5 ng/mL bFGF. On Day 2, cells 
were differentiated to definitive endoderm (DE) with serum free differentiation (SFD) 
medium containing 100 ng/mL Activin A. At Day 3, purity of the DE was assessed as 
described above. From Day 3-5, cells were cultured in DMEM/F12 medium with 1% fetal 
bovine serum (FBS) (Gibco), 50µg/ml stabilized ascorbic acid (SAA), 1.25 mM IWP2 
(Tocris), and 50 ng/ml FGF7 (R&D Systems). Medium was changed every day. On Day 
6 and 7, cells were cultured in DMEM high glucose medium with 1% B27 without RA, 1X 
Glutamax (Gibco), 50µg/ml SAA, 0.5% ITS-X (Gibco), 50 ng/mL FGF7, 0.5µM SANT1 
(Sigma), 1µM retinoic acid (RA) (Sigma), 100nM LDN (Tocris), and 500nM Phorbol 12-
myristate 13-acetate (Tocris). Medium was changed daily. From Day 8-10, cells were 
cultured in DMEM high glucose medium with 1% B27 without RA, 1X Glutamax, 50µg/ml 
SAA, 0.5% ITS-X, 2 ng/mL FGF7, 0.5µM SANT1, 0.1µM RA, 100nM LDN, and 250nM 
Phorbol 12-myristate 13-acetate. Medium was changed daily. On Day 11 and 12 
cultured in MCDB131 base media with 20 mM D-glucose (Sigma), 2% FBS, 1X 
Glutamax, 0.5% ITS-X, 10µg/ml Heparin (Sigma), 10µM ZnSO4 (Sigma), 0.5µM SANT1, 
0.05µM RA, 200nM LDN, 1µM T3 (Sigma), 2µM ALK5i II (Enzo). Medium was changed 
daily. From Days 13-25, cells were cultured in MCDB131 base media with 20 mM D-
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glucose, 2% FBS, 1X Glutamax, 0.5% ITS-X, 10µg/ml Heparin, 10µM ZnSO4, 200nM 
LDN, 1µM T3, 2µM ALK5i II, 100nM g-secretase inhibitor XX (Calbiochem). Medium was 
changed every other day. Cells were harvested on Day 0, Day 3, Day 6, Day 8, Day 11, 
Day 13, and Day 25 for analysis. 
2.5 Genomic Analysis  
Cells were harvested on Day 12 of the hepatocyte differentiation by dissociation with 
0.25% Trypsin/EDTA (Gibco) for 4 minutes. RNA was extracted as described below and 
sent to Genewiz for library preparation and sequencing. Cells were harvested on Day 6 
and Day 8 of the pancreas differentiation as described above. RNA was extracted and 
sent to the Center for Applied Genomics Biorepository Core at the Children’s Hospital of 
Philadelphia for library preparation and sequencing. Data was analyzed using Rosalind 
(https://rosalind.onramp.bio/), with a HyperScale architecture developed by OnRamp 
BioInformatics, Inc. (San Diego, CA). Individual sample counts were normalized via 
Relative Log Expression (RLE) using DESeq2 R library (Love et al., 2014).  Read 
Distribution percentages, violin plots, identity heatmaps, and sample MDS plots were 
generated as part of the QC step. Deseq2 was also used to calculate fold changes and 
p-values and perform optional covariate correction. Clustering of genes for the final 
heatmap of differentially expressed genes was done using the PAM (Partitioning Around 
Medoids) method using the fpc R library. Hypergeometric distribution was used to 
analyze the enrichment of pathways, gene ontology, domain structure, and other 
ontologies. The topGO R library was used to determine local similarities and 
dependencies between GO terms in order to perform Elim pruning corrections. Several 
database sources were referenced for enrichment analysis, including Interpro (Mitchell 
et al., 2019), NCBI (Geer et al., 2009), KEGG (Kanehisa and Goto, 2000; Kanehisa et 
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al., 2017, 2019), MSigDB (Liberzon et al., 2011; Subramanian et al., 2005), REACTOME 
(Fabregat et al., 2018), WikiPathways (Slenter et al., 2018). Enrichment was calculated 
relative to a set of background genes relevant for the experiment. Gene set enrichment 
analysis was performed (Mootha et al., 2003; Subramanian et al., 2005) using a gene list 
comparing gene expression in dorsal pancreatic bud and hepatic cord tissues dissected 
from human embryos using laser capture technology (Jennings et al., 2017). The gene 
list was sorted by a p-value of <0.05, then by fold change. The top 200 upregulated 
genes were the most enriched in the dorsal pancreatic bud, and the top 200 
downregulated genes were most enriched in the hepatic cord. GSEA was performed on 
these subsets using the “gene_set” permutation and an FDR cutoff of 5%.   
2.6 RNA isolation and quantitative real time polymerase chain reaction  
Cells were harvested by dissociation with 0.25% Trypsin/EDTA for 4 minutes. Cellular 
RNA was isolated using the PureLink RNA Micro Scale Kit (Invitrogen) following the 
manufacturer’s protocol. Random hexamers (Invitrogen) were used with the SuperScript 
III Reverse Transcriptase System (Invitrogen) to synthesize cDNA from 500 ng of 
extracted RNA. Quantitative real time polymerase chain reaction (qRT-PCR) reactions 
were done in triplicate on a Roche LightCycler 480 II using SYBR Select Master Mix 
(Applied Biosystems). Serial dilutions of H9 embryonic stem cell genomic DNA were 
used to generate a standard curve, and TBP (Veazey and Golding, 2011) was used as a 
house keeping gene to determine relative gene expression levels. The primers that were 






Table 2.2. Table of forward and reverse primers used for qRT-PCR 
Gene Forward Primer Reverse Primer 
TBX3 5'-TGAGATGTTCTGGGCTGG-3' 5'-CTTACCAGCCACCATCCA-3' 
HNF4a  5-TCCAACCCAACCTCATCCTCCTTCTT-3' 5'TCCTCTCCACTCCAAGTTCCTGTT-3' 
AFP 5'-GTTTGTTCAAGAAGCCACTTAC-3' 5'-CACCCTGAAGACTGTTCATC-3' 
SERPINA1 5' - AGGGCCTGAAGCTAGTGGATAGT-3' 5'-TCTGTTTCTTGGCCTCTTCGGTGT-3' 
ALBUMIN 5'-GTGAAACACAAGCCCAAGGCAACA-3' 5'-TCCTCGGCAAAGCAGGTCTC-3' 
TBXT 5’-CAGTGGCAGTCTCAGGTTAAGAAGG-3’ 5’-CGCTACTGCAGGTGTGAGCAA-3’ 
EOMES 5’-TATTGTCGGCTTTGCCACAGGTCA-3’ 5’-ACTCAATCCCACTGCCCACTACAA-3’ 
FOXA2 5’-GCATTCCCAATCTTGACACGGTGA-3’ 5’-GCCCTTGCAGCCAGAATACACATT-3’ 
SOX2 5'-CCATCACCCACAGCAAAT-3' 5'-AGTCCAGGATCTCTCTCATAA-3' 
PDX1 5'-GGAGCTGGCTGTCATGTTG-3' 5'-CACTTCATGCGGCGGTTT-3' 
CDX2 5'-AAGGACGTGAGCATGTACCCTAGC-3' 5'-CACGTGGTAACCGCCGTAGTC-3' 
ISL1 5--CAGAAGGAGGACCGGGCTCTAAT-3' 5'-GACTGGCTACCATGCTGTTAGGTGTAT-3' 
MNX1 5'-AGAAGGCGGAAACCCACAGTGTAA-3' 5'-CCCAGAGACGTAAGCATAAACCCT-3' 
NKX6.1 5'-AAGAAGCACGCTGCCGAGATG-3' 5'-CCGAGTTGGGATCCAGAGGCTTATT-3' 
APOA2 5'-ATGTGTGGAGAGCCTGGTTTCTCA-3' 5'-AAGCTCTGGGCTCTTGACCTTCT-3' 
TTR 5'-ATGGGCTCACAACTGAGGAGGAAT-3' 5'-AGATGCCAAGTGCCTTCCAGTAAGA-3' 
TBP 5’- TTGCTGAGAAGAGTGTGCTGGAGATG-3 5’-CGTAAGGTGGCAGGCTGTTGTT-3’ 
 
2.7 Western Blot 
Cells were harvested with 1.5x Laemmli buffer (75 mM Tris-HCl3, 15% glycerol, 3% 
SDS, 3.75 mM EDTA, and 200 mM NaF). Cell lysates were boiled at 95oC for 10 
minutes and protein was quantified using Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific). Samples were aliquoted and diluted with 4x Laemmli buffer. 20 µg of protein 
from each sample were run on a 4%-12% Bis-Tris SDS-polyacrylamide gel (Invitrogen) 
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and transferred to a 0.45 µm pore size nitrocellulose membrane (Thermo Fisher 
Scientific). The membrane was stained with Ponceau S (Sigma-Aldrich) to ensure 
successful transfer. The membrane was washed with 1X TBS (Bio-Rad) with 0.1% 
Tween-20 (Sigma) (TBST), then blocked in 5% nonfat dry milk in TBST for 1 hour at 
room temperature. The membrane was probed with primary antibody diluted in 5% 
nonfat dry milk in TBST overnight at 4°C. The membrane was washed three times with 
TBST and placed in a horseradish peroxidase conjugated secondary antibody diluted in 
5% nonfat dry milk in 1X TBST for 1 hour at room temperature. The membrane was 
washed three times with TBST. Pierce ECL Western Blotting Substrate (Thermo Fisher 
Scientific) was added to the membrane and exposed onto HyBlot CL autoradiography 
film (Denville Scientific) to detect protein of interest. A list of antibodies used can be 
found in Table 2.3. 
2.8 Flow Cytometry  
Cells were harvested by dissociation with 0.25% Trypsin/EDTA for 3 to 5 minutes. For 
intracellular staining, cells were fixed with 1.6% paraformaldehyde (Electron Microscopy 
Science) for 30 minutes at 37°C. Cells were washed in 1X PBS (Corning), then 
permeabilized and stained in 1X saponin buffer (Biolegend). Primary and secondary 
antibodies were diluted to the appropriate concentrations in saponin buffer and cells 
were stained for thirty minutes each at room temperature. Following staining, cells were 
washed in saponin, and resuspended in FACS buffer (1X PBS (Corning) with 0.1% BSA 
(Sigma) and 0.1% sodium azide (Sigma)). For extracellular staining, conjugated primary 
antibodies were diluted to the appropriate concentration in FACS buffer and cells were 
stained for fifteen minutes at room temperate. Following the staining, cells were washed 
and resuspended in FACS buffer. All samples were analyzed on a CytoFLEX V2-Br-R2 
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flow cytometer (Beckman Coulter Life Sciences) and FlowJo Version 10.6.2 (Beckton 
Dickenson) software program. A list of antibodies used can be found in Table 2.3. 
Table 2.3: Primary and secondary antibodies  
Antibody Species Dilution and Application 
Source and Catalog 
Number 
TBX3 Goat Polyclonal IgG 1:200 for Western Blot Santa Cruz #sc-17871  
b-actin Mouse  1:2000 for Western Blot Santa Cruz #sc-81178 
CXCR4-APC Mouse 1:50 for flow cytometry BD #555976 
CD117-PE Mouse 1:100 for flow cytometry BD #340529 
HNF4a Rabbit Monoclonal IgG 1:100 for flow cytometry Cell signaling #3113 
AFP Mouse Monoclonal IgG1 1:400 for flow cytometry R&D Systems #MAB1368 
AAT Mouse Monoclonal IgG1 1:100 for flow cytometry Santa Cruz #sc-59438 
Albumin Rabbit Polyclonal IgG 1:1000 for flow cytometry  DakoCytomation #A0001 
PDX1  Rabbit Monoclonal IgG 1:1000 for Western Blot Cell Signaling #5679 
NKX6.1  Mouse Monoclonal IgG1 1:250 for flow cytometry  DSHB #F55A10 
PDX1- 
biotinylated 
Goat Polyclonal IgG 1:50 for flow cytometry R&D Systems #BAF2419 
c-peptide Rabbit Polyclonal IgG 1:100 for flow cytometry Cell Signaling #4593S 
GCG Mouse Monoclonal IgG1 1:1000 for flow cytometry  Santa Cruz #sc-514592 
SST Rat Monoclonal IgG2a 1:400 for flow cytometry Santa Cruz #sc-47706 
Mouse IgG1 - 
Alexa488 
Goat 1:400 for flow cytometry Jackson Immunoresearch # 115-545-
205 
Mouse IgG1 - 
647 
Donkey 1:400 for flow cytometry Jackson Immunoresearch # 715-606-
151 
Mouse IgG1 - 
PE 
Goat  1:400 for flow cytometry Jackson Immunoresearch #115-115-
205 
Rabbit IgG - 
Alexa 647 
Goat  1:400 for flow cytometry Jackson Immunoresearch #111-605-
144 
Rabbit IgG - 
Alexa 488 
Goat 1:400 for flow cytometry Jackson Immunoresearch #111-545-
144 
Rat IgG - APC Goat 1:400 for flow cytometry ThermoFisher Scientific #A21247 
Streptavidin 
Pacific Blue 
  1:400 for flow cytometry Invitrogen #S-11222 
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2.9 Cytochrome P450 activity assay 
The cytochrome p450 activity assay was performed using P450-GloTM CYP3A4 
Luciferin-IPA kit (Promega, V9002). On Day 22 of the hepatocyte differentiation, cells 
were cultured with 25 μM Rifampicin (Sigma) or with DMSO (Tocris) as a vehicle control. 
To confirm that the induced activity was specific for CYP3A4 enzyme, inhibition controls 
included the selective inhibitor ketoconazole at 1 μM (Sigma) in the presence of 25 μM 
Rifampicin. Net signal was calculated by subtracting background luminescence values 
(no-cell control) from Rifampicin or DMSO values. Luminescence values were 
normalized for 5x105 cells to account for differences in cell numbers between wells.  
2.10 Statistical Analysis 
Results from multiple experiments are expressed as the mean ± standard error of the 
mean (SEM).  An unpaired two-tailed Student’s t test for groups with equal variance was 
performed to determine p values. All statistical analyses were performed on Prism 
version 8.4.3 for Mac (GraphPad Software). In the figures, *p<0.05, **p<0.01, 









CHAPTER 3: IMPACTS OF LOSS OF TBX3 ON HEPATOCYE AND PANCREAS 
DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS 
 
3.1 Introduction 
The liver and pancreas play vital roles in metabolism and digestion. Both organs arise 
from the posterior foregut region of the developing gut tube (Deutsch et al., 2001). The 
gut tube is characterized by an expression pattern of different transcription factors that 
specify distinct domains for each of the endodermal organs. While the hepatic and 
pancreatic domains of the gut tube lie in close proximity to each other, they are specified 
by different signals. FGF from the cardiac mesoderm (Gualdi et al., 1996; Jung et al., 
1999) and BMP4 from the septum transversum specify the hepatic endoderm (Rossi et 
al., 2001). Activin and FGF2 signals from the notochord, and retinoic acid from the 
lateral plate mesoderm specify the dorsal pancreatic endoderm (Hebrok et al., 1998). 
The transcription factor TBX3 has been shown to be involved in development in a 
number of model systems. TBX3 drives mesendoderm in Xenopus and mouse embryos 
(Weidgang et al., 2013), and has been  implicated in limb and heart development 
(Gibson-Brown et al., 1998; Singh et al., 2012). TBX3 is a member of the T-box gene 
family, with both repressor and activator domains, but is thought to act predominantly as 
a transcriptional repressor (Carlson et al., 2001; Naiche et al., 2005). In humans, 
heterozygous mutations in TBX3 result in Ulnar-Mammary Syndrome (UMS), a disorder 
causing defects in limb, mammary, and apocrine gland development (Bamshad et al., 
1997). Tbx3 has also been implicated in liver development, as it is expressed in 
hepatoblasts, bipotential progenitors that give rise to hepatocytes and cholangiocytes, 
which comprise the liver bud. Tbx3-/- mice have small liver buds that fail to expand and 
mature (Lüdtke et al., 2009). Tbx3 promotes a hepatocyte fate by maintaining 
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expression of hepatic transcription factors in hepatoblasts, while repressing 
cholangiocyte-specific genes (Suzuki et al., 2008). Tbx3 has been detected in the mouse 
pancreas, both during development and in the adult, but its function is unknown (Begum 
and Papaioannou, 2011). The role of TBX3 in human liver and pancreas development 
remains unclear.  
Pluripotent stem cells (PSCs), such as human embryonic stem cells (ESC) and induced 
pluripotent stem cells (iPSC) can give rise to all cell types, and are a model system for 
studying human development, physiology and disease. PSCs are easily manipulated 
using CRISPR/Cas9 genome editing technology, making them valuable for studying the 
role of specific genes in development and disease (Cong et al., 2013; Maguire et al., 
2019). Protocols to differentiate PSCs to both hepatocytes (Ogawa et al., 2013; Si-
Tayeb et al., 2010) and pancreatic b-cells (D’Amour et al., 2006; Nostro et al., 2011; 
Pagliuca et al., 2014; Rezania et al., 2014) have been established and improved 
drastically over time. However, it is still difficult to generate functionally mature terminal 
cell types in vitro.   
Here we use PSCs to study the role of TBX3 in human liver and pancreas development. 
TBX3 mutant PSC lines were generated using CRISPR/Cas9 genome editing, and 
differentiated into hepatocytes and pancreatic progenitors. The loss of TBX3 caused a 
defect in hepatocyte differentiation, similar to what was seen in Tbx3-/- mouse embryos. 
Interestingly, the loss of TBX3 resulted in the expression of PDX1 mRNA, a master 
regulator for pancreas development (Ahlgren et al., 1996; Stoffers et al., 1997) during 
the hepatocyte differentiation. Furthermore, PSCs lacking TBX3 differentiated more 
efficiently to pancreatic progenitors compared to wildtype PSCs. These data suggest 
that TBX3 may regulate liver development through suppression of pancreatic genes. A 
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better understanding of how TBX3 regulates pancreatic precursor efficiency may provide 
a potential avenue to improve generation of in vitro-derived pancreatic b-cells for use in 
therapeutic contexts. 
3.2 Results  
3.2.1 Loss of TBX3 impairs hepatocyte differentiation in human PSCs 
To study the role of TBX3 in human liver development, a TBX3 mutant line was 
generated in the CHOPWT4 iPSC background using CRISPR/Cas9 genome editing 
technology. Two guide RNAs (gRNAs) were designed to generate a 6.9 Kb deletion that 
includes the transcriptional start site and the entire DNA binding domain, rendering a 
non-functional protein (Figure 3.1A). The deletion in both alleles was verified by 
sequencing (Figure 3.6A) and confirmed to have a normal karyotype (Figures 3.6B). The 
genome-edited line is termed iPSC-/-, and the unedited line, designated as iPSC+/+, was 
used as an isogenic control (Table 3.1). To confirm the phenotype in a second genetic 
background, we generated TBX3 mutations in the Mel1 ESC line (Micallef et al., 2012) 
using the same strategy (Figure 3.6C-D), referred to as ESC-/- (Table 3.1).  
Table 3.1 TBX3 mutant pluripotent stem cell lines  
Name Genetic Background  Allele 1 Allele 2 
iPS+/+ CHOP WT4 Wild type Wild type 
iPS-/- CHOP WT4 6.9 Kb deletion 6.9 Kb deletion 
ES+/+ Mel1-INS-GFP Wild type Wild type 
ES-/- Mel1-INS-GFP 6.9 Kb deletion 6.9 Kb deletion 
 
TBX3 is not expressed in human PSCs (Esmailpour and Huang, 2012), therefore control 
and mutant lines were differentiated into hepatocytes using a modified protocol (Ogawa 
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et al., 2013) to verify loss of TBX3 at the mRNA and protein levels (Figure 3.1B). In 
iPSC+/+ cells, TBX3 expression was induced at day 6 (definitive endoderm stage) of 
differentiation, and peaked at day 12 (hepatoblast stage). TBX3 was not expressed in 
the iPSC-/- line during the differentiation at the mRNA or protein level (Figure 3.1C-D).  
Liver marker gene expression was analyzed in the differentiated iPSC cell cultures to 
determine the impact of TBX3 loss on human liver development. There was no 
difference in HNF4a levels, but expression of hepatoblast marker a-fetoprotein (AFP) 
was delayed in the iPSC-/- line. Tbx3-/- mice develop a normal liver bud, but generate a 
small liver due to impaired migration out of the gut tube epithelium (Lüdtke et al., 2009), 
suggesting that Tbx3 is not required for hepatoblast specification, but rather for 
maturation. This explains the subtle effect observed on hepatoblast marker expression in 
the differentiation of the iPSC-/- line. A more severe defect was observed later in the 
differentiation, as expression of hepatocyte markers SERPINA1, encoding a1-antitrypsin 
(AAT) protein, and ALBUMIN were significantly reduced in iPSC-/- cells compared to 
iPSC+/+ cells (Figure 3.1E). At the protein level, there were fewer HNF4a+/AFP+ cells 
(Figure 3.1F-G) and AAT+/ALBUMIN+ cells (Figure 3.1H-I) from the iPSC-/- line compared 
to the iPSC+/+ line. End-stage iPSC-/- hepatocytes treated with rifampicin had significantly 
reduced CYP3A4 activity compared to iPSC+/+ hepatocytes, indicating that the TBX3 is 
needed for hepatocyte functionality (Figure 3.1J). Similar defects were seen in the ESC-/- 
line (Figure 3.7A - 3.7I). It is possible that the ESC line is more sensitive to the loss of 
TBX3, explain why expression levels of HNF4a and AFP are lower in this line compared 
to the iPSC-/- line. However, the overall phenotype of TBX3 impairing hepatocyte 
differentiation is the same in both PSC lines. These results indicate that the loss of TBX3  
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impairs the ability of PSCs to differentiate to hepatocytes, suggesting that TBX3 is 
important in both mouse and human liver development. 




Figure 3.1: Loss of TBX3 impairs hepatocyte differentiation in the iPSC-/- line 
(A) Schematic of endogenous TBX3 locus with sites of gRNAs indicated above exons. 
Schematic underneath represents TBX3 locus after 6.9 kb deletion, resulting in a mutant 
TBX3 PSC line.   
(B) Schematic of directed differentiation protocol of PSCs to hepatocytes.  
(C) Time-course analysis of TBX3 expression during hepatocyte differentiation by qRT-
PCR (n =5 per time point, per cell line).  
(D) Western blot analysis of TBX3 protein in Day 12 iPSC+/+ and iPSC-/- hepatoblasts.  
(E) Time-course analysis of hepatoblast (HNF4a and AFP) and hepatocyte (SERPINA1 
and Albumin) markers during hepatocyte differentiation by qRT-PCR (n = 5 per time 
point, per cell line).  
(F) Analysis of hepatoblast markers HNF4a and AFP at Day 15 and Day 25 of 
differentiation by intracellular flow cytometry (one representative replicate shown). 
(G) Time-course analysis percentage HNF4a+/AFP+ cells by intracellular flow cytometry 
(n = 5 per time point, per cell line). 
(H) Analysis of hepatocyte markers AAT and ALBUMIN at Day 15 and Day 25 of 
differentiation by intracellular flow cytometry (one representative replicate shown).  
(I) Time-course analysis of percentage of AAT+/ALBUMIN+ cells in iPSC+/+ and iPSC-/- 
lines by intracellular flow cytometry (n = 5 per time point, per cell line).  
(J) Rifampicin-induced CYP3A4 activity in iPSC+/+ and iPSC-/- hepatocytes at Day 25 of 





3.2.2 Pancreas-specific genes are upregulated in TBX3 knockout cells  
Tbx3 drives mesendoderm differentiation in Xenopus and mouse embryos (Weidgang et 
al., 2013). We examined expression of early lineage markers to ensure that the 
hepatocyte defect we observed is not due to impaired mesendoderm or definitive 
endoderm differentiation. There was no difference in expression of mesoderm marker 
TBXT, mesendoderm marker EOMES, or definitive endoderm marker FOXA2 between 
the iPSC+/+ and iPSC-/- lines (Figure 3.2A). This demonstrates that the loss of TBX3 does 
not impact mesendoderm differentiation, and highlights a potential species-specific 
difference in TBX3 function during early development. Next, we examined whether loss 
of TBX3 affected gut tube patterning. The developing gut tube displays a well-
established expression pattern of transcription factors that specify different organ 
domains (Zorn and Wells, 2009) (Figure 1.1). To determine if the loss of TBX3 affected 
gut tube patterning, the expression of SOX2, CDX2, and PDX1, which specify the 
anterior gut tube, posterior gut tube, and pancreatic endoderm respectively, were 
examined. There was no impact on the expression of SOX2, and a minor upregulation of 
CDX2 in the iPSC-/- line. There was a large increase in expression of PDX1 in the iPSC-/- 
line compared to the iPSC+/+ line (Figure 3.2B). This was surprising as PDX1 is not 
normally expressed when using a hepatocyte differentiation protocol. Western blot 
analysis did not detect PDX1 protein in the mutant line (Figure 3.2C). PDX1 protein 
levels are tightly regulated by ubiquitination and proteasomal degradation (Claiborn et 
al., 2010), providing a possible explanation for the increase in PDX1 mRNA but not 
PDX1 protein in the hepatocyte differentiation. Additionally, expression of ISL1 (Ahlgren 
et al., 1997) and MNX1 (Harrison et al., 1999; Li et al., 1999), genes involved in early 







Figure 3.2: Pancreatic genes are expressed in the iPSC-/- line during hepatocyte 
differentiation  
(A) Time-course analysis of mesoderm (TBXT), mesendoderm (EOMES), and endoderm 
(FOXA2) markers during definitive endoderm differentiation by qRT-PCR (n = 3 per time 
point, per cell line).  
(B) Time-course analysis of anterior gut tube (SOX2), pancreatic endoderm (PDX1), and 
posterior gut tube (CDX2) markers during hepatocyte differentiation by qRT-PCR. (n = 5 
per time point, per cell line). PDX1 expression in iPSC+/+ differentiated to pancreatic 
endoderm for (+) control (n = 6). (C) Western blot analysis of PDX1 protein in Day 15 
iPSC+/+ and iPSC-/- immature hepatocytes and control EndoC-βH1 cell line.  
(D) Time-course analysis of early pancreatic markers ISL1 and MNX1 during hepatocyte 





a loss of repression of pancreatic genes. Similar results were also seen the ESC-/- line 
(Figure 3.8A-3.8D). PDX1 drives PSCs to a pancreatic fate during differentiation in part 
by repression of hepatic-specific genes, including TBX3 (Teo et al., 2015). The 
upregulation of PDX1, ISL1, and MNX1 in the iPSC-/- line suggests that TBX3 may be 
suppressing their expression in order to drive PSCs to a hepatocyte fate. Evidence of 
TBX3 regulating cell fates exists, as it promotes a hepatocyte over cholangiocyte fate in 
hepatoblasts (Suzuki et al., 2008). Further studies to the relationship between TBX3 and 
PDX1 are needed. Assay for transposase-accessible chromatin sequencing (ATAC-seq) 
experiments can identify how chromatin accessibility changes for different genes, 
particularly at pancreatic gene loci, with the loss of TBX3. Additionally, chromatin 
immunoprecipitation sequencing (ChIP-seq) studies can identify direct targets of TBX3 
at the hepatoblast stage. These studies may help to determine whether PDX1 and TBX3 
cross-regulate each other to maintain lineage fidelity of pancreatic and hepatic domains 
respectively during foregut patterning.  
3.2.3 Loss of TBX3 enhances pancreatic progenitor generation from PSCs  
Considering that TBX3 loss led to de-repression of pancreatic genes during in vitro liver 
differentiation, we tested whether a lack of TBX3 enhanced in vitro pancreatic 
differentiation. The iPSC+/+ and iPSC-/- lines were differentiated to pancreatic progenitors 
using a modified version of an established protocol (Rezania et al., 2014) (Figure 3.3A). 
The iPSC-/- line generated a higher percentage of the PDX1+/NKX6.1+ pancreatic 
progenitor 2 (PP2) population compared to iPSC+/+ cells (Figure 3.3B-C). Though PDX1 
levels increased in the iPSC-/- hepatocyte differentiation, there was no difference in 







Figure 3.3: Loss of TBX3 enhances pancreatic progenitor generation in the iPSC-/- line 
(A) Schematic of directed differentiation protocol of PSCs to PP2 cells.  
(B) Flow cytometry analysis of the PP2 makers PDX1 and NKX6.1 at day 11 of differentiation 
(one representative replicate shown).  
(C) Quantification of the percentage of PDX1+/NKX6.1+ and PDX1+ cells in samples 
examined in (B) (n = 6 per cell line).  
(D) Time-course analysis of early pancreatic markers PDX1, NKX6.1, ISL1, and MNX1 
during pancreatic differentiation by qRT-PCR (n = 6 per time point, per cell line).  
(E) Time-course analysis hepatoblast (AFP and TTR) and hepatocyte (SERPINA1) markers 
during pancreatic differentiation by qRT-PCR (n = 6 per time, point per cell line).  
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is likely because the pancreatic differentiation protocol has factors that drive cells 
towards a pancreatic identity, and virtually all cells already express PDX1 (Figure 3.3C). 
However, NKX6.1 expression was higher in iPSC-/- PP2 cells compared to iPSC+/+ PP2 
cells. NKX6.1 is crucial for pancreatic progenitor identity and required for further 
differentiation to b-cells (Memon et al., 2018; Nostro et al., 2015; Rezania et al., 2013). 
Additionally, expression of ISL1 was markedly increased in iPSC-/- cells compared to 
iPSC+/+ cells, while there was a subtle increase in MNX1 expression in iPSC-/- cells 
(Figure 3.3D). We also examined hepatic gene expression during the pancreatic 
differentiation. Levels of hepatic genes were lower in in the iPSC-/- line compared to the 
iPSC+/+ line (Figure 3.3E), suggesting the loss of TBX3 generates a purer PP2 
population. Similar results were seen in the ESC-/- line (Figure 3.9A-3.9D). These data 
demonstrate that a lack of TBX3 improves differentiation efficiency and purity, as the 
TBX3 mutant PSC lines generated more PP2 cells with increased expression of 
pancreas genes and decreased expression of hepatic genes, compared to the wildtype 
PSC lines. This suggests a novel role for TBX3 in inhibiting pancreas differentiation.  
3.2.5 TBX2 does not compensate for the loss of TBX3 in hepatocyte or pancreas 
differentiation 
 TBX3 is part of the highly conserved T-box gene family. Specifically, it is part of the 
TBX2 subfamily which also includes TBX2, TBX4, and TBX5. TBX3 and TBX2 are highly 
homologous in both their sequence and structure. Their DNA-binding domain sequences 
are about 95% similar, while the repression domains share 67% homology  (Khan et al., 
2020). Additionally, TBX2 and TBX3 have several overlapping functions, both in 
development and cancer (Gibson-Brown et al., 1998; Lingbeek et al., 2002; Singh et al., 













Figure 3.4 TBX2 does not compensate for the loss of TBX3 in hepatocyte or 
pancreas differentiation 
(A) Time-course analysis of TBX2 expression during hepatocyte differentiation by qRT-
PCR (n = 4 per time point, per cell line). Wildtype in blue, TBX3-/- in red, and TBX2-/-
;TBX3-/- in green. The same color scheme follows for the remaining panels of this figure.  
(B) Time-course analysis of hepatoblast (HNF4a and AFP) and hepatocyte (SERPINA1 
and Albumin) markers during hepatocyte differentiation by qRT-PCR (n = 5 per time 
point, per cell line). 
(C) Time-course analysis pancreatic marker PDX1 during hepatocyte differentiation by 
qRT-PCR (n = 4 per time point, per cell line).  
(D) Flow cytometry analysis of the PP2 makers PDX1 and NKX6.1 at day 11 of 
differentiation (one representative replicate shown).  
(E) Quantification of the percentage of PDX1+/NKX6.1+ and PDX1+ cells in samples 




were examined during the hepatocyte differentiation. TBX2 is not normally expressed 
during the hepatocyte differentiation, but surprisingly, TBX2 levels increased in the 
absence of TBX3 (Figure 3.4A). To determine whether TBX2 compensates for the loss 
of TBX3, a TBX2 and TBX3 double knockout line termed TBX2-/-;TBX3-/- was generated. 
This line was differentiated to hepatocytes to confirm the knockout as there is no TBX2 
expression (Figure 3.4A), and to determine how the loss of TBX2 impacts hepatocyte 
differentiation. If TBX2 and TBX3 play a compensatory role in liver differentiation, the 
double knockout line was expected to have a more severe effect than the TBX3 single 
knockout alone. While hepatocyte differentiation was still impaired in the TBX2-/-;TBX3-/- 
line,  there was no significant difference between the double and TBX3 single knockout 
line (Figure 3.4B) This suggests that they do not compensate for each other, and that 
TBX3 plays a more significant role in hepatocyte differentiation.  
 
Similar to the TBX3 single knockout, there was an increase in PDX1 levels in TBX2-/-
;TBX3-/- cells during the hepatocyte differentiation (Figure 3.4C). Because PDX1 
expression was also increased in this line, we tested whether the loss of TBX2 impacted 
differentiation to PP2 cells. If TBX2 compensates for TBX3 act in the pancreas 
differentiation, we expect that the double knockout would generate pancreatic 
progenitors even more efficiently than the TBX3 single knockout line. Again, while the 
TBX2-/-;TBX3-/- line generated more PP2 cells compared to wildtype cells, there was no 
difference in the ability of the TBX3 single knockout and TBX2-/-;TBX3-/- lines to generate 
pancreatic progenitors (Figure 3.4D-E). Taken together, these results imply that TBX2 
does not compensate for the loss of TBX3 in either hepatocyte or pancreas 
differentiation. In both these developmental processes, the loss of TBX3 appears to 
have a large impact on the differentiation while the loss of TBX2 does not. Therefore, we 
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conducted gene expression studies to gain insight into how TBX3 may be acting in 
pancreas and liver development.  
3.2.5 iPSC-/- cells are enriched for a pancreatic gene signature  
To investigate the effect of the loss of TBX3 on pancreatic differentiation in greater 
detail, gene expression was examined using RNA-seq in iPSC-/- versus iPSC+/+ lines at 
days 6 and 8 of pancreas differentiation (Figure 3.5A and 3.10A). We chose day 6 as 
TBX3 expression peaked at this point in the differentiation, and was comparable to TBX3 
levels in day 12 during the hepatocyte differentiation (Figure 3.5B). This stage of 
differentiation is representative of the gut tube (GT) endoderm when endodermal cells 
begin patterning to the foregut. We also chose pancreatic progenitor 1 (PP1) cells at day 
8, which represents when cells first express the pancreas master regulator PDX1. At 
both the GT and the PP1 stages, pancreas specific genes were upregulated while 
hepatic genes were downregulated in iPSC-/- versus iPSC+/+ (Figure 3.10B and Figure 
3.5C). Pathway analysis showed that genes involved in metabolic pathways were 
downregulated in iPSC-/- GT cells compared to iPSC+/+ GT cells (Table 3.2), and 
pathways relating to pancreatic development and function were upregulated in iPSC-/- 
PP1 (Table 3.3). Interestingly, genes involved in axonal guidance were also enriched in 
iPSC-/- PP1 cells. This provides further evidence that these cells have enhanced 
pancreatic characteristics, as b-cells share many common features with neuronal cells 
(Arntfield and van der Kooy, 2011).  To determine if the gene expression signature of 
iPSC-/- cells in our in vitro differentiation was indicative of a pancreas commitment at the 
expense of liver fate, we used gene set enrichment analysis with a previously published 
gene set from primary human embryos comparing the dorsal pancreatic buds to hepatic 











Figure 3.5:  iPSC-/- PP1 cells are enriched for a pancreatic gene signature  
(A) Schematic of stages from PSC differentiations collected for RNA-seq analysis.  
(B) Time-course analysis of TBX3 expression by qRT-PCR during pancreatic 
differentiation (n = 6) and Day 12 hepatoblasts (n = 5) for comparison.  
(C) Volcano plot of downregulated and upregulated genes in iPSC-/- versus iPSC+/+ PP1 
(Day 8) cells. p-Adj = 0.05, fold change: > 1.5 and < -1.5. 
(D) GSEA analysis comparing normalized gene expression of samples examined in (C) 
to genes enriched in human fetal dorsal pancreatic bud and hepatic cord.  
(E) Heat map of genes identified by covariate meta-analysis that are commonly 
upregulated and downregulated in iPSC-/- versus iPSC+/+ cells at different developmental 
stages and tissues types. PP1 = pancreatic progenitor 1, PGT = Day 6 primitive gut 
tube, Hep = Day 12 hepatoblasts.  
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iPSC+/+ versus iPSC-/- GT cells, and pancreatic bud specific genes were significantly 
enriched in the iPSC-/- PP1 population (Figure 3.10C and Figure 3.5D). These data 
further confirm that the loss of TBX3 helped drive cells towards a pancreatic fate and 
away from a hepatic fate.  
Table 3.2: Top pathways downregulated in iPSC-/- primitive gut tube cells  
Pathway p-value Gene Symbols 
Glycosaminoglycan 
Metabolism 
1.2x10-4 FMOD, PRELP, HS3ST3B1, HS3ST1, DSE, 
HS3ST5, HS6ST2, ACAN, VCAN, PAPSS2, 
HS3ST3A1, CSGALNACT1, CHST2 
Cholesterol Biosynthesis 9.3x10-4 SQULE, FDFT1, HMGCS1, HMGCR, MSM01 
Metabolism of Lipids 1.6x10-3 BCHE, HPGD, PLD1, FABP7, RGL1, 
PPARGC1A, ALB, SQLE, PISD, INSIG1, 
SEC24D, FDFT1, OSBPL10, ACOT12, ACSM3, 
STARD4, HMGCS1, ELOVL5, ABHD4, GPX2, 
PRKD1, SPTSSB, HMGCR, MSMO1, ARSG, 
HSD17B11, GC, AHR, CYP4A11, ACOT2, 
PTGS1, PLA2G16, GPD1L, PIP5K1B, ABCB4, 
CAV1, AKR1D1, PLA2G3 
Metabolism of Carbohydrates 4.9x10-3 FMOD, PRELP, SLC2A1, ALDH1A1, HS3ST3B1, 
HS3ST1, MANBA, DSE, SLC2A3, HS3ST5, 
HS6ST2, ACAN, PFKP, VCAN, PAPSS2, 
SLC2A14, HS3ST3A1, CSGALNACT1, 
PPP1R3C, CHST2 
 
Table 3.3: Top pathways upregulated in iPSC-/- PP1 cells 
Pathway p-value Gene Symbols 
Regulation of gene expression in early 
pancreatic precursor cells 
5.310-6 PDX1, PTF1A, ONECUT1, NKX6.1 
Axon Guidance  1.7x10-4 TN1, DPYSL4, SEMA6D, EPHB3, 
PLXNA1, DSCAM, RGMA, 
PLXNA2, PSMB8, PRKCQ, 
SEMA5A, DPYSL5, KCNQ2, 
SCN3B, EPHA7, UNC5C, EPHB1, 
CACNB2, CACNA1D, SRGAP3, 
ABLIM3, SH3GL2 
Interferon Signaling  6.2x10-4 HLA-B, TRIM46, TRIM3, MT2A, 
PSMB8, EGR1, HLA-C, STAT1, 
HLA-DQB1 
Regulation of beta-cell development  5.4x10-3 PDX1, PTF1A, ONECUT1, NKX6.1 
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Additional characterization was performed using RNA-seq analysis of iPSC-/- versus 
iPSC+/+ day 12 hepatoblasts (Figure 3.5A). PROX1, which is required for hepatoblast 
migration and is downregulated in Tbx3-/- mice (Lüdtke et al., 2009), and CDH2, a 
mesenchymal cell marker, were downregulated in iPSC-/- hepatoblasts, suggesting a 
migratory defect. Hepatoblast markers HNF4a and AFP were slightly upregulated in 
iPSC-/- hepatoblasts, because the hepatocyte defect was not apparent until later in the 
differentiation. Consistent with our prior gene expression findings, PDX1, ISL1, and 
MNX1 were upregulated in iPSC-/- hepatoblasts (Figures 3.10D). To better understand 
the global changes in gene expression due to the loss of TBX3, a covariate meta-
analysis was performed to identify commonly dysregulated genes in iPSC-/- cells at three 
developmental stages: PGT and PP1 cells from the pancreatic differentiation, and 
hepatoblasts from the hepatocyte differentiation. The covariate analysis showed 1398 
genes similarly upregulated or downregulated in all three developmental stages (Figure 
3.5E). Several pathways, including epithelial-mesenchymal transition (EMT) and TNFa 
signaling via NF-kB were dysregulated with the loss of TBX3 regardless of cell type 
(Table 3.4), suggesting a common role of TBX3 in these processes during pancreas and 
liver development. Taken together these data highlight potentially novel functions of 
TBX3, and present possible commonalities in liver and pancreas development.  
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Table 3.4 Genes commonly up- and down-regulated in iPSC-/- primitive gut tube, 
PP1, and hepatoblast cells 
Pathway p-value Gene Symbols 
Epithelial-Mesenchymal 
Transition  
5.3x10-8 VEGFA, WNT5A, DKK1, DAB2, CRLF1, GREM1, 
AB13BP, ECM2, CADM1, VCAN, GJA1, 
PCOLCE2, LAMC1, PVR, CDH2, LAMA3, 
LAMC2, MATN2, SNTB1, VEGFC, FBN1, 
COL12A1, COL11A1, FBN2, MATN3, CYR61, 
NT5E, GADD45B, OXTR, ITGAV, TGFBI, IL6, 
LOX, COL6A3, COL5A1, MMP1, FMOD, 
TNFRSF12A, GLIPR, 
TNFa Signaling Via NF-kB  8.1x10-4 VEGFA, LAMB3, DDX58, CD83, ACKR3, JAG1, 
IL7R, EFNA1, G0S2, SPHK1, EGR1, FOSL2, 
MARCKS, DUSP4, PTGS2, F2RL1, LDLR, 
PTPRE, CYR61, HBEGF, SLC16A6, GADD45B, 
CSF1, EDN1, KLF4, IL6, PDE4B, IL1A, IL18 
Pancreas Beta Cells 3.2x10-4 CSK2, ISL1, PDX1, SST, PAX6, DCX, NKX6.1, 
AKT3, DPP4 
Inflammatory Response 3.3x10-3 RGS1, FZD5, IL7R, MSR1, TACR1, CD82, 
CSF3R, SPHK1, PIK3R5, P2RY2, IL2RB, PVR, 
AHR, TAPBP, LDLR, PTPRE, ITGB8, HBEGF, 
CSF1, EDN1, IL6, PDE4B, PTAFR, IL1A, 
SLC7A1, IL18, SCN1B 
 
3.3 Discussion  
This study investigates the role of TBX3 in both human liver and pancreas development. 
Our findings demonstrate that TBX3 is needed for hepatocyte differentiation, suggesting 
that it functions similarly in the mouse and human. Unexpectedly, the loss of TBX3 
results in pancreatic gene expression during the hepatocyte differentiation, raising the 
possibility that TBX3 drives liver development through repression of pancreas-specific 
genes. This led us to examine how TBX3 impacts pancreas differentiation. We found 
that TBX3 mutant PSCs generate a higher yield of pancreatic progenitors with an 
enhanced pancreatic gene signature. Further genomic analysis demonstrated that 
epithelial-mesenchymal transition (EMT) is commonly dysregulated in both pancreas 
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and liver development, presenting a potentially common function for TBX3 in these 
processes.  
TBX3 is known to play a role in EMT in several different biological contexts. TBX3 
promotes invasiveness of breast cancer and melanoma cells through direct regulation of 
EMT genes SLUG (Krstic et al., 2019) and E-cadherin (Rodriguez et al., 2008), 
respectively. During liver bud expansion, hepatoblasts undergo EMT and delaminate into 
the surrounding mesenchyme. Tbx3-/- mice maintain E-cadherin expression, indicating a 
failure in EMT and subsequent liver bud expansion (Lüdtke et al., 2009). In pancreas 
development, endocrine progenitors undergo EMT and delaminate from the branching 
epithelium into the surrounding mesenchyme to form pancreatic islets (Gouzi et al., 
2011). Although Tbx3 expression has been observed in the developing and adult mouse 
pancreas, its role is unclear. Tbx3 was detected in the pancreatic mesenchyme during 
budding and early morphogenesis (Zhou et al., 2007) near branching epithelial tubes 
(Begum and Papaioannou, 2011).  Based on the role of TBX3 in regulating EMT in other 
biological contexts, it may function similarly in delamination during islet formation. 
Cytoskeletal structure influences delamination (Kesavan et al., 2014) and differentiation 
(Mamidi et al., 2018) in the mouse, and enhances PP2 generation from PSCs (Hogrebe 
et al., 2020). We show that loss of TBX3 enhances PP2 generation, highlighting possible 
links between TBX3, cytoskeletal state, and differentiation.  
This study provides insight into the biology of patterning of the hepatic and pancreatic 
domains during foregut development. We established that TBX3 is critical for proper 
hepatocyte development and maturation in humans, similar to the role of Tbx3 in mouse 
liver development. We also demonstrate that lowering TBX3 levels optimizes the quality 
and number of pancreatic progenitors derived from PSCs. These results enhance the 
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knowledge of early endoderm development, and provide a methodology to improve the 
generation of in vitro derived pancreatic progenitors, which can be further differentiated 





Figure 3.6: Characterization of TBX3 mutant PSC lines  
(A) Sequencing of the region to verify deletion in both alleles of the TBX3 locus in the 
iPSC-/- line. Bars represent locations of TBX3 gRNA1 and TBX3 gRNA2.  
(B) Karyotype of iPSC-/- line. 
(C) Sequencing of the region of the gRNA sequences to verify deletion in both alleles of 
endogenous TBX3 locus inthe ESC-/- line.  Bars represent locations of TBX3 gRNA1 and 
TBX3 gRNA2.  















Figure 3.7: Loss of TBX3 impairs hepatocyte differentiation in the ESC-/- line 
(A) Time-course analysis of TBX3 expression during hepatocyte differentiation by qRT-
PCR. (n = 3 per time point, per cell line).  
(B) Western blot analysis of TBX3 protein in Day 12 ESC+/+ and ESC-/- hepatoblasts.  
(C) Time-course analysis of hepatoblast (HNF4a and AFP) and hepatocyte (SERPINA1 
and ALBUMIN) markers during hepatocyte differentiation by qRT-PCR (n = 3 per time, 
point per cell line).  
(D) Analysis of hepatoblast markers HNF4a and AFP at Day 15 and Day 25 of 
differentiation by intracellular flow cytometry (one representative replicate shown).  
(E) Time-course analysis of percentage of HNF4a+/AFP+ cells by intracellular flow 
cytometry (n = 3 per time point, per cell line).  
(F) Analysis of hepatocyte markers AAT ad ALBUMIN at day 15 and Day 25 of 
differentiation by intracellular flow cytometry (one representative replicate shown).  
(G) Time-course analysis of percentage of AAT+/ALBUMIN+ cells by intracellular flow 
cytometry (n = 3 per time point, per cell line).  
(H) Rifampicin-induced CYP3A4 activity in ESC+/+ and ESC-/- hepatocytes at Day 25 of 








Figure 3.8: Pancreatic genes are expressed in the ESC-/- line during hepatocyte 
differentiation  
(A) Time-course analysis of mesoderm (TBXT), mesendoderm (EOMES), and endoderm 
(FOXA2) markers during definitive endoderm differentiation by qRT-PCR (n = 3 per time 
point, per cell line).  
(B) Time-course analysis of anterior gut tube (SOX2), pancreatic endoderm (PDX1), and 
posterior gut tube (CDX2) markers during hepatocyte differentiation by qRT-PCR (n = 3 
per time point, per cell line). PDX1 expression in ESC+/+ differentiated to pancreatic 
endoderm for (+) control (n = 5). (C) Western blot analysis of PDX1 protein in Day 15 
ESC+/+ and ESC-/- immature hepatocytes and control EndoC-βH1 cell line.  
(D) Time-course analysis of early pancreatic markers ISL1 and MNX1 during hepatocyte 







Figure 3.9: Loss of TBX3 enhances pancreatic progenitor generation in the ESC-/- 
line 
(A) Flow cytometry analysis of the PP2 makers PDX1 and NKX6.1 at day 11 of 
differentiation (one representative replicate shown).  
(B) Quantification of the percentage of PDX1+/NKX6.1+ and PDX1+ cells in samples 
examined in (D) (n = 5 per cell line).  
(C) Time-course analysis of early pancreatic markers PDX1, NKX6.1, ISL1, and MNX1 
during pancreatic differentiation by qRT-PCR (n = 5 per time point, per cell line).  
(D) Time-course analysis hepatoblast (AFP, TTR, ApoA2, and ApoB) markers during 








Figure 3.10: iPSC+/+ PGT and hepatoblast cells are enriched for hepatic gene 
signature  
(A) Sample correlation of heatmap correlating samples of same replicate group, 
developmental stage, and genotype. PGT = Day 6 primitive gut tube, PP1 = Day 8 
pancreatic progenitor, Hep = Day 12 hepatoblasts.  
(B) Volcano plot of downregulated and upregulated genes in iPSC-/- versus iPSC+/+ 
primitive gut tube (Day 6) cells. p-Adj = 0.05, fold change: > 1.5 and < -1.5.  
(C) GSEA analysis comparing normalized gene expression of samples examined in (B) 
to genes enriched in human fetal hepatic cords and dorsal pancreatic bud.  
(D) Volcano plot of downregulated and upregulated genes in iPSC-/- versus iPSC+/+ 
hepatoblasts cells. p-Adj = 0.05, fold change: > 1.5 and < -1.5. 
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CHAPTER 4: SUMMARY AND SPECULATIONS 
4.1 Summary of Findings  
In these studies, we used human PSCs lines to investigate the role of TBX3 in human 
liver and pancreas development. Our findings demonstrate that TBX3 is important for 
human liver development, in part by negatively regulating pancreatic gene expression. 
TBX3 mutant PSCs differentiate more efficiently to pancreatic progenitors, as these cells 
have enhanced pancreatic gene expression at the expense of hepatic genes. RNA-
sequencing analysis determined that genes involved in epithelial-mesenchymal 
transition are commonly dysregulated in both liver and pancreas cells, suggesting a 
common role for TBX3 in these developmental processes. These findings provide insight 
into how TBX3 functions during liver and pancreas development, but several questions 
still remain. This work presents potential avenues for improving pancreatic progenitor 
generation from PSCs that need further investigation. These future studies can help 
improve PSC-derived b-cells for use in therapeutic treatments for diabetes.  
4.2 Enhancing cholangiocyte differentiation from PSCs 
One role for Tbx3 in mouse liver development is to drive hepatocyte differentiation and 
suppress a cholangiocyte fate. Tbx3-/- mouse embryos have increased expression of 
cholangiocyte-specific genes and decreased expression of hepatocyte genes. Part of the 
work in this thesis investigates the role of TBX3 in human liver development, and how it 
impacts hepatocyte differentiation. We find that the loss of TBX3 significantly impairs 
hepatic gene expression and functionality. However, whether the loss of TBX3 enhances 
the ability of PSCs to differentiate to cholangiocytes remains unclear.  
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During liver development, a small subset of hepatoblasts adjacent to the portal 
mesenchyme differentiate into cholangiocytes which mature to form intrahepatic bile 
ducts (IHBDs) (Zong and Stanger, 2012). Portal mesenchyme cells express Jagged-1, a 
ligand activating the Notch signaling pathway, and its receptor Notch2 is expressed on 
neighboring hepatoblasts. Notch activation reduces the expression of the hepatic 
transcription factors Hnf1a, Hnf4a, and C/ebpa while increasing the expression of Hnf1b 
in these hepatoblasts, promoting cholangiocyte differentiation (Tanimizu and Miyajima, 
2004). Notch activation also induces expression of Sox9 (Zong et al., 2009), which 
promotes a cholangiocyte fate by repressing Cebp/a (Antoniou et al., 2009). This results 
in increased levels of the transcription factor Hnf6 (Shiojiri et al., 2004; Yamasaki et al., 
2006) which is upstream of Hnf1b, and are both important for cholangiocyte 
differentiation. Both Hnf6-/- and Hnf1b-/- mice have fewer IHBDs compared to their 
wildtype counterparts (Clotman et al., 2002; Coffinier et al., 2002), demonstrating they 
are required for proper cholangiocyte differentiation and IHBD formation. Additionally, 
Hnf6, and its homolog Onecut2 (Oc2) regulate cholangiocyte development by creating a 
TGFb signaling gradient, with TGFb signaling being high near the portal vein. Upon 
deletion of both Hnf6 and Oc2, the TGFb gradient in the developing liver is disrupted, 
resulting in hybrid cells that have characteristics of both hepatocytes and cholangiocytes 
(Clotman et al., 2005). These studies highlight the bipotential nature of hepatoblasts and 
how the delicate balance of transcription factor expression dictates a cholangiocyte or 
hepatocyte fate. Understanding the role of TBX3 in influencing these fate decisions in 
humans is important for improving protocols to drive PSCs towards a cholangiocyte fate.   
Preliminary data show that TBX3 mutant lines have a slight increase in levels of 
cholangiocyte markers SOX9 and CK19 during a second maturation phase described in  
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Figure 4.1: Cholangiocyte marker expression in TBX3 mutant PSCs 
  
Figure 4.1 Cholangiocyte marker expression in TBX3 mutant PSCs  
(A) Schematic representation of the hepatocyte differentiation protocol with second 
hepatocyte maturation phase.  
(B) Time-course analysis of cholangiocyte markers SOX9 and CK19 by qRT-PCR at the 
end of the hepatocyte differentiation in wildtype (blue) and TBX3 knockout (red) PSCs. 




the original hepatocyte differentiation protocol (Figure 4.1A-B). This suggests that not 
only does the loss of TBX3 impair hepatocyte differentiation, but may also enhance 
cholangiocyte differentiation. An explanation for the subtle increase in cholangiocyte 
markers is that the differentiation conditions support hepatocyte maturation rather than 
cholangiocyte maturation. To fully address whether cells lacking TBX3 adopt a 
cholangiocyte fate over a hepatocyte fate, wildtype and TBX3 mutant PSCs need to be 
differentiated to cholangiocytes using established protocols (Ogawa et al., 2015; 
Sampaziotis et al., 2015). Cells would be collected at different time points during the 
differentiation and assayed for cholangiocyte marker expression, including SOX9, CK19, 
and NOTCH2. End-stage cholangiocytes would be assayed for maturation markers, 
morphology, and functionality to determine if a lack of TBX3 can enhance cholangiocyte 
differentiation. This would have potential biological and clinical implications. First, these 
experiments would provide further insight into how TBX3 influences hepatoblast fate 
decisions during human liver development. Secondly, it may allow for enhanced 
generation of PSC-derived cholangiocytes that can be used for disease modelling, drug 
discovery and development, or for use in therapeutic contexts such as cystic fibrosis 
treatment.  
Tbx3 maintains expression of hepatic transcription factors Hnf4a and C/ebpa, allowing 
for hepatoblast proliferation and delamination via an epithelial-mesenchymal (EMT) like 
process. Conversely, Tbx3-deficient cells express cholangiocyte markers Hnf6 and 
Hnf1b, have reduced proliferation and do not delaminate, and differentiate to 
cholangiocytes (Lüdtke et al., 2009). It remains unclear whether Tbx3 promotes a 
hepatocyte fate over a cholangiocyte fate by regulating EMT. Further studies to 
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characterize the relationship between TBX3 and EMT can provide insight into the 
mechanism of how it regulates fate decisions during development.  
4.3 TBX3 and epithelial-mesenchymal transition in pancreas differentiation  
Our RNA-sequencing analysis revealed that in TBX3 mutant cells, genes involved in 
epithelial-mesenchymal transition (EMT) were commonly dysregulated in both the liver 
and pancreas differentiations. This suggests that TBX3 may have a common role in 
regulating EMT in during these developmental processes.  
Briefly, EMT is a process by which epithelial cells lose their classic characteristics and 
adopt properties of mesenchymal cells. Upon EMT induction, epithelial cells lose their 
apical-basal polarity and cellular junctions that hold the cells together. Downregulation of 
epithelial cadherin (E-cadherin) is a hallmark of EMT. E-cadherin repression is mediated 
by several transcription factors including SNAIL, SLUG, and TWIST. As EMT 
progresses, the cells take on the spindle-shaped morphology of mesenchymal cells, and 
begin to express mesenchymal markers such as neural cadherin (N-cadherin) and 
vimentin. The underlying basement membrane degrades and the extracellular matrix 
(ECM) is remodeled, allowing cells to migrate into the surrounding stroma. EMT is 
involved in many developmental processes, as well as in wound healing and cancer 
progression (Dongre and Weinberg, 2019).  
In liver development, EMT occurs during liver bud formation and hepatoblast migration. 
As the liver bud thickens, the basement membrane degrades and hepatoblasts migrate 
into the surrounding mesenchyme. This process is controlled by several transcription 
factors including Tbx3. Tbx3-/- embryos fail to downregulate E-cadherin and the 
basement membrane does not degrade, preventing hepatoblast migration, and thus liver 
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bud expansion (Lüdtke et al., 2009). The fact that EMT was dysregulated in our TBX3 
mutant hepatoblasts correlates with the phenotype observed in Tbx3-/- mouse embryos, 
providing further evidence that TBX3 acts similarly during liver development in both 
species. Additionally, TBX3 has been shown to advance tumor invasiveness in several 
types of cancer by directly regulating genes involved in EMT (Krstic et al., 2016; 
Rodriguez et al., 2008). TBX3 is clearly involved in EMT regulation in many different 
biological contexts, raising the possibility that TBX3 may also facilitate EMT during 
pancreas development. 
An EMT-like process is thought mediate endocrine cell delamination during pancreas 
development. As endocrine progenitors differentiate and mature, they delaminate from 
the epithelial branches and migrate into the surrounding mesenchyme to form pancreatic 
islets (Gouzi et al., 2011; Rukstalis and Habener, 2007). Additionally, the actin 
cytoskeleton plays an important role in pancreas development. Blocking F-actin 
disassembly prevents b-cell delamination from the trunk epithelium, and impairs b-cell 
function and development (Kesavan et al., 2014). Cytoskeleton state also mediates 
differentiation earlier in pancreas development during differentiation to either a ductal or 
endocrine cell fate (Mamidi et al., 2018). Recently, manipulating actin polymerization 
was shown to improve b-cell differentiation from PSCs, further demonstrating the 
relationship between cytoskeleton and differentiation (Hogrebe et al., 2020). Hogrebe 
and colleagues find that blocking actin polymerization prevents premature expression of 
the endocrine marker NGN3, and allows for expression of the pancreatic progenitor 
marker NKX6.1, which is important for enhancing b-cell generation from PSCs (Nostro et 
al., 2015; Rezania et al., 2013). Thus, the cytoskeleton influences pancreatic 
differentiation by regulating the timing of transcription factor expression. 
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Figure 4.2: Pancreatic hormone production in TBX3 mutant PSCs 
 
 
Figure 4.2: Pancreatic hormone production in TBX3 mutant PSCs 
(A) Analysis of b-cell markers NKX6.1 and INSULIN at Day 25 of differentiation by 
intracellular flow cytometry (one representative replicate shown).  
(B) Quantification of mean fluorescence intensity (MFI) from flow cytometry of Insulin, 
Glucagon, and Somatostatin in ESC+/+ and ESC-/- cells at Day 25 of pancreas 
differentiation. MFI represented as normalized to wildtype (n = 4 per line).  
(C) Quantification of mean fluorescence intensity (MFI) from flow cytometry of C-peptide, 
Glucagon, and Somatostatin in iPSC+/+ and iPSC-/- cells at Day 25 of pancreas 
differentiation. MFI represented as normalized to wildtype (n = 4 per line). 
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Our findings suggest that the loss of TBX3 enhances pancreatic progenitor generation 
from PSCs. We postulate that this likely due to de-repression of pancreatic genes rather 
than changes in cytoskeletal state. However, preliminary data suggest that upon further 
differentiation, TBX3 mutant PSCs generate very few insulin-producing cells (Figure 
4.2A). There were lower levels of glucagon (a-cells) and somatostatin (d-cells) in TBX3 
mutant PSCs as well (Figure 4.2B-C), indicating a failure in differentiation past the 
pancreatic progenitor stage. This raises the possibility that TBX3 plays a role later in 
pancreas development and differentiation. Because our RNA-sequencing data show that 
genes involved in EMT are dysregulated in the TBX3 mutant line during the pancreas 
differentiation, and since TBX3 is known to regulate EMT, we suggest a novel role for 
TBX3 in regulating EMT and/or cytoskeleton state during endocrine cell delamination 
from the pancreatic epithelium.  
We propose a model in which TBX3 has a biphasic role depending on the stage of 
pancreas development. This phenomenon is quite common for transcription factors, 
especially during pancreas development. Early in development, TBX3 plays an 
antagonistic role, skewing the cells toward a hepatic lineage and away from a pancreatic 
fate (Figure 4.3A). Later, TBX3 may be required for endocrine cell delamination and 
differentiation by mediating EMT and the cytoskeleton state (Figure 4.3B). Although 
Tbx3 expression has been detected in the developing mouse pancreas, it is mainly 
restricted to the mesenchyme surrounding the pancreatic epithelium, and its function is 
unknown (Begum and Papaioannou, 2011; Zhou et al., 2007). Interestingly, Tbx2, but 
not Tbx3, is expressed in pancreatic endocrine tissue in the mouse (Begum and 
Papaioannou, 2011). In human embryos, TBX3 is expressed in SOX9+/PTF1A+ tip 
progenitors, which give rise to exocrine component of the pancreas (Villani et al., 2019).  
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Figure 4.3 Proposed biphasic role for TBX3 during pancreas development 
Figure 4.3: Proposed biphasic role for TBX3 during pancreas development 
(A) Early in development, TBX3 plays an inhibitory role by repressing pancreatic gene
expression, thus skewing cells towards a hepatic fate and away from a pancreatic fate.
(B) Later, TBX3 may function in endocrine cell delamination by regulating epithelial-
mesenchymal transition, presenting a novel role for TBX3 in pancreas development.
Created with BioRender.com
This is not seen in the mouse, suggesting a possible species-specific difference in TBX3 
expression and function during pancreas development. Alternatively, this may be an 
example of distinct T-box family members being used for the same function in different 
species, with Tbx2 acting in mouse and TBX3 acting in human pancreas development. 
Because TBX3 is present in pancreatic tip progenitors, it may also be present in trunk 
cells of the pancreatic epithelium, which gives rise to endocrine progenitors. If this is the 
case, TBX3 may be mediating EMT in endocrine cell differentiation and delamination 
from the trunk during islet formation. Further characterization of TBX3 expression in the 
developing human pancreas is needed. Since TBX3 mutant PSCs differentiate poorly to 
b-cells, further studies to determine a link between TBX3, EMT, and/or the cytoskeletal
state are also required. These studies would investigate how this relationship may 
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impact pancreas differentiation, and provide insight into methods of improving both 
pancreatic progenitor and b-cell generation from PSCs.  
4.4 Applications for in vitro differentiation of PSCs to pancreatic b-cells  
Generating pancreatic b-cells from PSCs is an area of great interest. PSC-derived b-
cells are immensely advantageous not only for studying b-cell biology, but also for 
clinical applications such as disease modelling and treating diabetic patients. 
Differentiation protocols have been continuously improving over time, bringing the field 
closer to generating functionally mature b-cells from PSCs. Our studies contribute to this 
goal by examining how TBX3, which has not been previously studied in pancreas 
differentiation, impacts pancreatic progenitor and b-cell differentiation from PSCs.  
We propose that TBX3 expression may be used as an indicator for how well a particular 
PSC line differentiates to pancreatic progenitors. It is common that different PSC lines 
have variable differentiation efficiencies even when using the same protocols. This can 
be attributed to differences in genetic background such as endogenous gene expression 
and signaling or DNA methylation state (Ortmann and Vallier, 2017). Differentiation 
efficiencies are particularly variable when generating b-cells from patient-derived iPSCs, 
presenting a significant challenge in using these lines for disease modelling or 
therapeutic purposes.  Levels of endogenous TBX3 can vary amongst PSC lines, which 
may impact their ability to differentiate to pancreatic progenitors. Because TBX3 
promotes hepatic gene expression, PSC lines with high levels of TBX3 may differentiate 
less efficiently to pancreatic lineages. Thus, lowering endogenous TBX3 expression by 
manipulating signaling pathways may help improve pancreas differentiation efficiency, 
especially in patient-specific iPSC lines.  
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Tbx3 is a known downstream target of the Wnt/b-catenin pathway (Eblaghie et al., 2004; 
Renard et al., 2007), which plays an inhibitory role during early pancreas development 
(McLin et al., 2007). The pancreas protocol utilizes a WNT inhibitor early in the 
differentiation to mimic gut tube anteriorization, but it is removed in later stages (Rezania 
et al., 2014). Keeping the WNT inhibitor in the differentiation medium longer until the 
pancreatic progenitor 1 (PP1) stage may reduce TBX3 levels, and improve pancreatic 
progenitor differentiation. However, in our differentiations, we see that TBX3 expression 
is high, even in the presence of the WNT inhibitor, and TBX3 levels decline after the 
WNT inhibitor is removed. This suggests that TBX3 expression is not under the control 
of WNT signaling in this context, and additional manipulations may reveal a mechanism 
to reduce endogenous TBX3 levels to improve pancreatic differentiation efficiency.  
The BMP pathway is another a promising candidate for controlling TBX3 levels during 
the pancreas differentiation. Tbx3 has been implicated as a downstream target of the 
Bmp pathway in several developmental processes (Tumpel et al., 2002; Yang et al., 
2006). Furthermore, the Bmp pathway inhibits pancreatic specification while promoting 
hepatic specification (Rossi et al., 2001). The protocol uses a BMP inhibitor to drive the 
cells to pancreatic progenitor stages (Rezania et al., 2014). Interestingly, TBX3 
expression levels peak at the gut tube stage, and are drastically reduced upon addition 
of the BMP inhibitor to the differentiation medium. In lines with poor pancreas 
differentiation due to high endogenous TBX3 levels, adding the BMP inhibitor earlier in 
the differentiation protocol may reduce TBX3 levels prior to the gut tube stage and help 
skew the cells towards a pancreatic lineage, thus improving differentiation to the 
pancreatic progenitor stage. 
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Additionally, TBX3 expression levels can be used as a readout while testing various 
small molecules to improve pancreas differentiation. TBX3 expression is not only 
controlled by the WNT/b-catenin and BMP pathways, but is also under the influence of 
sonic hedgehog (Lüdtke et al., 2016) and retinoic acid signaling (Ballim et al., 2012). All 
four of these signaling pathways are involved in pancreas development, thus 
manipulating their activity could help to further improve differentiation protocols. 
Changes that result in lower levels of TBX3 expression can help determine which 
conditions are ideal for pancreatic differentiation. Controlling the timing and levels of 
signaling pathway activity to lower TBX3 levels is a promising and relatively 
straightforward method for enhancing pancreas differentiation from PSCs. Being able to 
generate a large number of pure pancreatic progenitors is important because it improves 
the chances of producing mature and functional b-cells from PSCs. Moreover, 
manipulating signaling pathways can reduce TBX3 levels without disrupting the gene, 
bypassing any potential issues if TBX3 is needed later in pancreatic development.  
4.5 Summary and conclusions 
In summary, this thesis explores the role of TBX3 in human liver development. Using 
TBX3 mutant PSC lines, we found that TBX3 is required for proper hepatocyte 
differentiation by maintaining hepatic gene expression, and influencing EMT. This is 
similar to Tbx3 function in mouse liver development, highlighting the conserved role 
between species. Surprisingly, we found that the loss of TBX3 results in reduced hepatic 
gene expression and increased expression of pancreatic genes in the context of both 
hepatocyte and pancreas differentiation protocols (Figure 4.4A). This suggests that 
TBX3 may control liver versus pancreas fate by repressing pancreatic gene expression, 
uncovering a novel role for TBX3 during endoderm patterning and differentiation. We 
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also found that TBX3 mutant PSCs generate more pancreatic progenitors compared to 
wildtype PSCs, further implying that TBX3 hinders pancreas differentiation. However, 
TBX3 mutant PSCs differentiate less efficiently to b-cells, suggesting that it may be 
required later in differentiation (Figure 4.4B). Further studies into the mechanism of how 
TBX3 impacts pancreas differentiation and development are needed. One possibility is 
that TBX3 mediates EMT or influences the cytoskeletal state during development. 
Reducing TBX3 levels may be one way to improve both the quality and quantity of PSC-
derived pancreatic progenitors, which can then be differentiated to b-cells. Generating 
functionally mature b-cells from PSCs has been an important goal in the pancreas 
biology field. Existing protocols have been continuously evolving, yet there are still 
improvements that can be made. Not only does the work in this thesis uncover a novel 
role for TBX3 in endoderm development, it also provides a new method for improving 
PSC-derived pancreatic progenitors, which can then be further differentiated to b-cells 
for use in therapeutic contexts. 
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Figure 4.4: Summary of loss of TBX3 in b-cell differentiation from PSCs 
Figure 4.4: Summary of loss of TBX3 in b-cell differentiation from PSCs 
(A) High TBX3 levels promotes increased hepatic gene expression during the pancreatic
differentiation. (B) Loss of TBX3 enhances pancreatic progenitor generation (PP2,
purple cell). However, TBX3 may be required for b-cell differentiation, as TBX3 knockout
cells generate b-cells less efficiently. Wildtype conditions are shown in black arrows, and
effects of TBX3 knockout are shown in red arrows. Thickness of arrows indicates
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